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Abstract 
  
 Opiates represent the most commonly used drugs for the treatment of 
moderate-to-severe postoperative and chronic pain. Chronic use of opioids can induce 
paradoxical hyperalgesia (opioid-induced hyperalgesia; OIH). OIH is characterized 
by hypersensitivity to innocuous or noxious stimuli during sustained opiate 
administration, and is reported both in clinical and pre-clinical settings but its molecular 
mechanisms are not fully understood. One of the mechanisms that contribute to OIH is 
the activation of brain areas involved in pain facilitation. Here we studied the 
involvement of an area located in the medulla oblongata, the dorsal reticular nucleus 
(DRt), which plays a unique and exclusive pain facilitatory role. The studies included in 
the present thesis aimed at i) determining whether chronic administration of morphine 
induces OIH in acute pain and the spared nerve injury (SNI) model of chronic 
neuropathic pain; ii) study the effects of chronic morphine on morphine reward and iii) 
evaluate the involvement of the DRt in the mediation of OIH and morphine reward. 
 To determine the effects of chronic morphine administration the animals were 
implanted with osmotic mini-pumps filled with morphine (45 μg.μl-1.h-1) or saline, which 
released their content continuously for 7 days. The effects of chronic morphine 
administration on pain behavior were tested before and at 2, 4 and 7 days after the 
mini-pump implantation. In naïve animals pain behavior was tested by the von-Frey 
and hotplate test which evaluate mechanical allodynia and thermal hyperalgesia 
respectively. Pain assessment in SNI animals was performed by the von-Frey test, the 
pin-prick test which evaluate changes in mechanical hyperalgesia and the acetone test 
to assess cold allodynia. The continuous infusion of morphine induced OIH in naïve 
animals and, for the first time, we show that chronic morphine administration induced 
OIH in an animal model of neuropathic pain. 
 To study the effects of chronic morphine on the reward behavior we used the 
conditioned place preference test (CPP). In animals chronically treated with morphine, 
the acute administration of morphine failed to induce CPP, unlike in control animals, 
which indicates a loss of the reward effect of morphine.   
  To study the involvement of the DRt in the mediation of OIH, we first 
inactivated the DRt with lidocaine (0.5 µl; 4% w/v) in naïve animals. The injection of 
lidocaine was performed on day 7 after implantation of the osmotic pumps containing 
saline or morphine (45 μg.μl-1.h-1) and its effects were tested by behavioral tests 
mentioned above. The administration of lidocaine at the DRt fully reversed mechanical 
allodynia and thermal hyperalgesia in morphine-infused animals. Then we studied the 
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expression of the phosphorylated cAMP response element-binding protein (pCREB) 
and µ-opioid receptor (MOR), at the DRt, by immunohistochemistry. We show that 
chronic morphine treatment induces an increase of pCREB and MOR expression and 
that MOR immunoreactive cells co-localized with pCREB. Finally, we performed a 
lentiviral-mediated knock-down of the expression of MOR at the DRt. For that, the 
animals were stereotaxically injected with lentiviral vectors at the DRt and implanted 
with osmotic mini-pumps containing saline or morphine (45 μg.μl-1.h-1). The animals 
were tested before and 7 days after the lentiviral injections and mini-pump implantation 
by the behavioural tests mentioned above. The knock-down of MOR in control animals 
showed an increase of pain behaviours. In animals chronically treated with morphine, 
the knock-down of MOR prevented the development of OIH. We also evaluated the 
effects of MOR knock-down to assess the involvement of the DRt in morphine reward 
during chronic morphine exposure. Our preliminary results show that MOR knock-down 
results in a reversion of the loss of morphine reward. 
 Our results indicate that chronic morphine exposure induces OIH in naïve and 
neuropathic animals and, that the DRt is involved in the mediation of OIH, likely 
through MOR activation whose effects appear switch from inhibitors to facilitation upon 
chronic morphine. Our results also indicate that chronic morphine treatment induces a 
loss of morphine reward and that the DRt might also be involved in the mediation of 
such effects through MOR activation. Given the increase in the expression of pCREB 
at the DRt, it would be interesting to explore the involvement of this transcription factor 
in pain transmission from the DRt, during opioid-induced hyperalgesia.  It would also be 
interesting to explore the interactions between the DRt and brain areas involved both in 
pain and reward on morphine reward. 
 
 
 
Keywords: Opioid-induced hyperalgesia; Dorsal reticular nucleus; µ-opioid receptor; 
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Resumo 
  
 Os opióides representam um dos tratamentos mais comuns tanto para o 
tratamento da dor pós-operativa como para o da dor crónica. O uso crónico de 
opióides promove um efeito paradoxal, a hiperalgesia induzida por opióides (HIO). 
HIO é caracterizada por uma hipersensibilidade a estímulos inócuos ou nocivos 
durante a administração crónica de opióides, relatada tanto em ambientes clínicos 
como pré-clínicos mas os mecanismos moleculares subjacentes não estão ainda 
totalmente elucidades. Um dos mecanismos que contribui para a HIO é a activação de 
áreas supra-espinhais envolvidas na facilitação da dor. Neste trabalho estudou-se o 
envolvimento de uma área localizada no bolbo raquidiano, o núcleo reticular dorsal 
(DRt), que desempenha um papel exclusivo na facilitação da dor. Os estudos incluídos 
na presente tese visam a i) determinar se a administração crónica de morfina induz 
HIO em modelos de dor aguda ou de lesão do nervo ciático, (o modelo “spared nerve 
injury”- SNI), um modelo de dor crónica neuropática; ii) estudar os efeitos da 
exposição crónica a morfina sobre os efeitos de recompensa da morfina e iii) avaliar o 
envolvimento do DRt na mediação da HIO e nos efeitos de recompensa da morfina. 
 Para determinar os efeitos da administração crónica de morfina, os animais 
foram implantados com mini-bombas osmóticas contendo morfina (45 μg.μl-1.h-1) ou 
soro, que permite a libertação contínua do seu conteúdo, durante 7 dias. Os efeitos da 
administração crónica de morfina no comportamento nociceptivo foram testados antes 
e aos 2, 4 e 7 dias após a implantação das mini-bombas. Em animais naïve o 
comportamento nociceptivo foi testado pelo teste de von-Frey e pelo teste de Hotplate 
que avaliam alodinia mecânica e hiperalgesia térmica, respectivamente. O 
comportamento nociceptivo em animais SNI foi realizado através do teste de von Frey, 
o teste de pin-prick que avalia hiperalgesia mecânica e pelo teste da acetona que 
avalia alodinia ao frio. A infusão contínua de morfina induziu HIO em animais naïve e, 
pela primeira vez, foi mostrado que a administração contínua de morfina induz HIO 
num modelo animal de dor neuropática. 
 Para estudar os efeitos do tratamento crónico com morfina no comportamento 
de recompensa foi utilizado o teste de “conditioning place preference” (CPP). Em 
animais cronicamente tratados com morfina, a administração aguda de morfina não 
induziu CPP, ao contrário dos animais controlo, o que indica uma perda do efeito de 
recompensa da morfina. 
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 Para estudar o envolvimento do DRt na mediação da HIO, primeiro inactivou-se 
o DRt com lidocaína (0,5 mL; 4% m/v) em animais naïve. A injecção de lidocaína foi 
realizada no sétimo dia após a implantação das bombas osmóticas contendo morfina 
(45 μg.μl-1.h-1) ou soro e, os seus efeitos foram testados pelos testes comportamentais 
já mencionados. A administração de lidocaína na DRt reverteu totalmente a alodinia 
mecânica e hiperalgesia térmica nos animais tratados com morfina. Em seguida, 
estudou-se a expressão da proteína de ligação ao elemento de resposta ao AMP 
cíclico (pCREB) e do receptor μ-opióide (MOR), no DRt, por imuno-histoquímica. 
Mostrou-se que o tratamento crónico com morfina induziu um aumento da expressão 
de pCREB e MOR e as células marcadas com MOR apresentam uma percentagem 
elevada de co-localização com pCREB. Por fim, foi realizada uma diminuição da 
expressão, “knock-down”, de MOR através de vetores lentivíricos no DRt. Para isso, 
os animais foram injetados com vectores no DRt e implantados com mini-bombas 
osmóticas contendo morfina (45 μg.μl-1.h-1) ou soro. Os animais foram testados antes e 
7 dias após a injecção com os lentivírus e implantação de mini-bombas osmóticas, 
pelos testes comportamentais já mencionados. A diminuição de expressão de MOR 
em animais de controlo, induziu um aumento da sensibilidade à dor. Em animais 
tratados cronicamente com a morfina, o knock-down de MOR impediu o 
desenvolvimento de OIH. Também foram avaliados os efeitos do knock-down de MOR 
no DRt nos efeitos de recompensa da morfina durante a exposição crónica de morfina. 
Os resultados preliminares demonstram que a diminuição de expressão de MOR 
resulta numa pequena reversão da perda do efeito de recompensa da morfina. 
 Os resultados obtidos indicam que a exposição crónica à morfina induz HIO em 
animais naïve e neuropáticos e, que o DRt está envolvido na mediação de HIO, 
provavelmente através da ativação de MOR cujos efeitos parecem mudar de inibidores 
para facilitadores após a exposição prolongada de morfina. Os resultados obtidos 
também indicam que o tratamento crónico com morfina induz uma perda do efeito de 
recompensa da morfina e que o DRt também pode estar envolvido na mediação 
desses efeitos, através da ativação de MOR. Dado o aumento da expressão de 
pCREB no DRt, seria interessante no futuro explorar o envolvimento deste factor de 
transcrição na transmissão da dor a partir do DRt, durante a hiperalgesia induzida por 
opióides. Também seria interessante explorar as interações entre o DRt e as áreas 
cerebrais envolvidas tanto na dor como no efeito de recompensa da morfina. 
Palavras-chave: Hiperalgesia induzida por opióides; Núcleo reticular dorsal; Recetor 
-opióide; Efeito de recompensa;  
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Introduction 
 
1. Pain  
 
1.1 Pain definition 
 According to the International Association for the Study of Pain (IASP), pain is 
defined as an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage [1].  Acute pain has a 
protective role. The capacity to experience pain alert us of imminent or actual tissue 
damage and leads to a behavioural response to minimize negative outcomes.  On the 
other hand, persistent pain syndromes offer no biological advantage. Chronic pain 
persists beyond the expected normal time for healing, 3-6 months, and has no 
physiological purpose [2]. 
 Pain can be considered a high plasticity process that leads to several changes 
in the neural structure and some of those changes are so drastic, specially chronic 
pain, that pain cannot be considered just a symptom but, instead, it should be 
considered as a pathological state [3]. 
 Chronic pain is a major healthcare problem in Europe, it affects approximately 
20% of the adult population, particularly women and elderly [4]. In Portugal it is 
estimated that 30 % of the population suffers from chronic pain [5]. Chronic pain may 
be inflammatory, neuropathic or functional and all forms share some common 
characteristics [3]. Inflammatory pain is caused by tissue damage occurring mainly 
after trauma, surgery or during chronic inflammatory diseases, having damaged and 
inflammatory cells recruited to the damaged tissue that release activators of peripheral 
nociceptors [3, 6]. Neuropathic pain is  defined by IASP as a direct consequence of a 
lesion or disease affecting  the  somatosensory  system  [1],  in  other  words,  it  is  
classified  as  an  association  of  spontaneous pain and hypersensitivity with 
pathological changes in the peripheral  nervous  system (PNS)  or in the central  
nervous system (CNS) [3]. Functional pain is a relatively new concept and is defined as 
pain sensitivity caused by an abnormal processing or function of the CNS in response 
to normal stimuli and may occur in fibromyalgia and irritable bowel syndrome [3]. 
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1.2 Pain Transmission 
 
 Primary afferent neurons innervate cutaneous tissues, bone, muscle, 
connective  tissues, vessels and viscera and nociception occurs when these neurons 
are activated by noxious stimuli [3, 7]. Primary afferent axons can be categorized by 
their peripheral targets, conduction velocity, response properties and neurochemical 
phenotype [8]. Aδ-fibers are characterized as medium cell bodies, thinly myelinated 
fibers and conduct at intermediate velocities; Aȕ-fibers have larger cell bodies and are 
heavily myelinated; C-fibers have small cell bodies, unmyelinated fibers and conduct 
action potentials slowly [3, 5, 8, 9]. C- and Aδ-fibers are able to encode noxious 
chemical, thermal and mechanical stimuli and, for this reason, are considered the main 
nociceptive afferents signaling pain [9]. 
 Primary afferent neurons convert noxious stimuli into electrical activity in 
peripheral terminals, causing depolarization of the neuronal membrane. If the stimuli 
are translated into a sufficiently intense electrical signal, voltage gated sodium 
channels will be activated generating the transmission of stimuli to central terminals of 
nociceptors in the spinal cord. The impulses generated in the dorsal horn travel through 
second order neurons, which constitute the ascending pathways to thalamus and 
brainstem where information is processed and pain is perceived, resulting in an 
appropriate response, transported by descending pathways to the spinal dorsal horn 
(Figure 1) [3, 10].  
 More recently, attention has focused on spinal cord projections to the 
parabrachial region of the dorsolateral pons, because the output of this region provides 
for a rapid connection with the amygdala,  a  region  usually  considered  to  process  
information  relevant  to  the  aversive  properties  of  pain  experience [11]. From these 
brainstem and thalamic loci, information reaches cortical structures [11, 12]. There is 
no single brain area essential for pain. Rather, pain results from activation of a group of 
structures, some of which are more related with the sensory-discriminative properties, 
such as the somatosensory cortex, and others with the emotional aspects, such as the 
anterior cingulate gyrus and insular cortex. Imaging studies demonstrated  activation of 
prefrontal cortical areas, as well as regions not generally associated with pain 
processing such as the basal ganglia and cerebellum, but the contribution of the  
activation of these areas to pain perception is not well understood [9]. 
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Figure 1: Transmission of nociceptive information. Nociceptive information is carried by primary afferent neurons from 
the periphery to the spinal cord and then reaches the brainstem through ascending pathways constituted by second 
order neurons.  In  the  brain   nociceptive  information  is  evaluated  and  an  appropriate  response  is  generated and 
conveyed by  descending pathways to the dorsal horn of spinal cord.  Adapted from Tavares & Martins [13]. 
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1.3 Descending pain modulation 
 
1.3.1 The endogenous pain control system 
 
 The endogenous pain control system is a complex web of brain areas 
responsible for modulating pain transmission at the spinal cord. It is involved in pain 
inhibition and, more recently was discovered to be also involved in pain facilitation [14, 
15]. 
 Several supraspinal sites play an important role in pain modulation but, the 
most well characterized pain modulatory areas are the mesencephalic periaqueductal 
grey (PAG) and the rostral ventromedial medulla (RVM) (Figure 2) [16]. 
 The PAG is connected with the hypothalamus and limbic forebrain structures 
including the amygdala, and also receives direct spinomesencephalic input. The PAG 
is also connected with the RVM, which in turn sends its output to the spinal dorsal horn 
[15]. The RVM is the final common relay in descending modulation of nociception from 
the PAG, since the PAG does not project directly to the spinal cord, and other 
supraspinal sites (Figure 2 and 4) [14, 15]. The RVM is constituted by the nucleus 
raphe magnus and adjacent reticular formation and projects to superficial layers of 
dorsal horn laminae and to deep dorsal horn [15]. In this area there are two distinct 
types of cells classified as ON- and OFF- cells, which exert facilitatory and inhibitory 
effects, respectively, on nociception. This two distinct populations of neurons project to 
the dorsal horn and µ-agonists affect these two types of cells by direct inhibition of ON-
cells and by disinhibition of OFF-cells [17-19]. 
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Figure 2:  Schematic representation of the pain modularity circuitry.  Primary afferent neurons convey nociceptive inputs 
to the spinal dorsal horn. From the dorsal horn there are ascending projections (labelled in red) targeting the thalamus, 
the DRt, the RVM and the PAG. The thalamus is connected to some cortical sites and to the amygdala. Descending 
pain modulation is mediated through projections (labelled in green) from these cortical areas to the PAG, which 
communicates with the RVM and the LC, and send descending projections to the spinal dorsal horn. Areas labelled “i–
iv” in the small diagram correspond to labelled details of the larger diagram. Abbreviations: DRt - dorsal reticular 
nucleus; RVM- rostral ventromedial medulla ; PAG- mesencephalic periaqueductal grey; LC- locus coeruleus. Adapted 
from Ossipov et al [14] 
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1.3.2 The dorsal reticular nucleus   
 
 The dorsal reticular nucleus (DRt) belongs to the endogenous pain control 
system and deserves special attention since this area will be focus of the present 
thesis.  
 The DRt is located in the most caudal portion of the medullary dorsolateral 
reticular formation, more specifically, in the dorsolateral quadrant of the medulla 
oblongata [20].This area is located medially to the spinal trigeminal nucleus, pars 
caudalis (Sp5C), laterally to the nucleus tractus solitaries (Sol), ventral to the nucleus 
cuneate (Cu) and dorsal to the  ventral reticular nucleus (VRt) (Figure 3)[20].   
 DRt neurons are exclusively activated by cutaneous or visceral noxious 
stimulation conveyed by Aδ- and C-fibers from the full body [20-23]. Glutamate 
administration in the DRt induces a long-lasting increase in the responsiveness of 
spinal nociceptive neurons [24], while lidocaine administration in the DRt results in the 
suppression of responsiveness [20]. At the behavioral level, the DRt was shown to be 
involved in pain facilitation both in acute and chronic pain models [25-27]. Recently, it 
was found that the facilitatory effects of the DRt, in inflammatory and neuropathic pain 
models, were mediated by noradrenaline release at the DRt [28, 29]. 
 
 
 
Figure 3: Diagram of a coronal section of the caudal medulla oblongata.  Abbreviations: DRt-Dorsal reticular nucleus; 
Cu-Nucleus cuneate; Sol-Nucleus tractus solitaries; Sp5C-Spinal trigeminal nucleus, pars caudalis; VLM-Caudal 
ventromedial medulla; VRt-Ventral reticular nucleus. Adapted from Paxinos and Watson [30]. 
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 The DRt receives projections from the spinal cord laminae I, IV–VII and X,  with 
a clear ipsilateral predominance of those originated in the dorsal horn and the  
connections between lamina I and  the  DRt  are  characterized  by  excitatory  synaptic  
contacts at both sites, which indicates that this reciprocal connection exerts excitatory  
actions at both spinal and DRt levels functioning thus as a reverberating system that  
leads to signal amplification[20]. 
 The DRt has connections with several brainstem areas such the ventrolateral 
medulla (VLM), PAG, RVM, locus coeruleus and the A5 and A7 noradrenergic cell 
groups. The DRt also projects to medial thalamus and the limbic system, which  
suggests an integration of DRt activity with emotional aspects of pain processing [16, 
23]. Furthermore, the DRt is connected with the extrapyramidal and orofacial motor 
system, which suggests an involvement of DRt in motor reactions associated with pain 
[23]. 
 
 
 
Figure 4: DRt involvement in pain modulating circuitries. Ascending connections are represented in red, descending  
projections are in blue and nociceptors are depicted in green. A–D are central nervous system sections and represent  
the  spinal  dorsal  horn  (A),  the  medulla  oblongata  and  pons  (B),  the mesencephalon  (C)  and  the  forebrain  
(diencephalon and telencephalon, D). Abbreviations: ACC, anterior cingulate cortex; Ins, insular cortex; Mot, Motor 
cortex; Som, somatosensory cortex; Hyp, hypothalamus. Adapted from Almeida et al[23]. 
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2. Opioids and pain 
 The Sumerians in Mesopotamia were among the earliest civilizations identified 
to have cultivated the poppy plant around 3400 BC [31]. Derived from opium poppy, 
opioids have been used for millennia for the treatment of moderate to severe pain [32, 
33]. Opioids play a unique role in society. They are widely feared compounds, which 
are associated with addiction but they are also essential medications commonly used 
to treat postoperative, cancerous, and, more recently, chronic nonmalignant pain [19, 
34] as consequence, opioids are among the most often prescribed drugs to treat pain 
[34]. 
 
2.1. Opioid receptors 
 
 Opioids activate peripheral, spinal and supraspinal opioid receptors. Currently 
there are four well-established groups of opioid receptors: µ (MOR), δ (DOR), κ (KOR) 
the and opioid receptor-like (ORL1) [18, 35, 36]. Subtypes of the receptors have been 
proposed. MOR is divided into two subtypes: MOR 1 mediates the analgesic and 
euphoric effects of opioids as well as the physical dependence and MOR 2 mediates 
the bradycardic and respiratory depressant effects. DOR, with two subtypes identified 
until now, DOR-1 and DOR-2, mediate spinal analgesic effects and have been 
associated to modulation of tolerance. The three KOR subtypes, KOR-1, KOR-2 and 
KOR-3, mediate spinal analgesia, miosis, sedation and diuresis [37]. 
 The opioid receptors belong to the large family of seven-transmembrane G-
protein-coupled receptors. The binding of opioids to the receptor results in a 
conformational change of the inhibitory Gi protein alternating from an inactive  
guanosine diphosphate (GDP) to an active guanosine triphosphate (GTP) which results 
in the activation of the α subunit of the G-protein. Once activated the α subunit 
dissociate from the ȕ and Ȗ subunits and binds to adenylate cyclase (AC) inhibiting it. 
As a consequence of the inhibition of AC the intracellular concentrations of cyclic 
adenosine monophosphate (cAMP) decrease, reducing phosphorylation and activation 
of multiple proteins resulting in decreased excitatory activity (Figure 5) [18, 35, 36]. 
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Figure 5: Seven transmembrane structure of opioid G-protein-coupled receptor. Receptor activation by opioid ligands 
leads to initiation of intracellular transduction pathways that include stimulation of potassium efflux, decrease of 
intracellular Ca2+ and inhibition of adenylyl cyclase resulting in decreased excitatory activity. Adapted from McDonald et 
al [38]. 
 
 MOR presents the widest distribution in the brain and spinal cord, while DOR 
and KOR have a more restricted distribution. In peripheral tissues, opioid receptors are 
responsible for the modulation of several physiological functions including alterations 
during inflammation, analgesia and tolerance [36]. The  ORL-1  has  been  detected  in  
the  amygdala septum, the hypothalamus, the thalamus, in the DRG and the spinal 
cord [39]. 
 
 Investigations in pain have focused predominantly on MOR because its 
activation is essential for the action of the most powerful analgesics as morphine, 
oxycodone and hydrocodone [35]. The opioid receptors are expressed both on pre- 
and post-synaptic neurons in the CNS and exert a major inhibitory influence in pain 
transmission at the spinal level, exerting their actions via MOR expression in pre-
synaptic primary sensory  neurons  and  in  post-synaptic secondary neurons [18, 35, 
36]. Furthermore, MOR is expressed in the main brain areas associated to pain 
modulation, such as the insular cortex, amygdala, hypothalamus, PAG, RVM [35, 36], 
DRt [40] and are abundantly expressed in the limbic system which is associated the 
emotional perception of pain [36]. 
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2.2. Effects of endogenous opioids in pain modulation 
 Opioid drugs act in peripheral, spinal, and supraspinal receptors which have 
endogenous ligands,  known as endogenous opioid peptides [36].  
 Endogenous opioids, which are naturally produced in the organism are involved 
in the modulation of pain and also in other behavioural processes, such as reward, 
dependency, sedation and stress response [41]. There are three families of 
endogenous peptides that produce several active peptides: pro-opiomelanocortin that 
produce ȕ-endorphin, proenkephalin that produce met- and leu-enkephalin peptides 
and prodynorphin  that produced dynorphins and neo-endorphins (Table 1) [36]. 
 
Table 1: Endogenous opioid peptides and their receptors. 
Precursor Name Receptor 
Proenkephalin Leu-enkephalin δ and µ 
Proenkephalin Met-enkephalin δ and µ 
Pro-opiomelanocortin ȕ-Endorphin µ and δ 
Prodynorphin Dynorphins Κ 
Unidentified Endomorphin-1 µ 
Unidentified Endomorphin-2 µ 
Pro-nociceptin/orphanin FQ Nociceptin/orphanin FQ ORL-1 
Adapted from Ren and Dubner [42] 
 The opioid peptides ȕ-endorphin, dynorphins and enkephalins are widely 
distributed throughout the brain,  whereas  in  the  spinal  cord  dynorphins  are  mainly  
present  in  interneurons. Spinal enkephalins  are  found  primarily  in  long  descending  
pathways  from  midbrain  to  the  dorsal horn. Opioid peptides are also synthetized in 
nonneuronal cells, such as endocrine cells and cells of the immune system [41]. 
 The enkephalins, activate mainly the DOR, while the dynorphins activate mainly 
the KOR (Table 1). The ȕ–endorphin peptide can produce a response through all three 
receptors although this response is stronger when it acts through MOR and DOR 
(Table 1) [41]. Two additional peptides endomorphin-1 and -2, with no precursor for 
endogenous synthesis identified so far, bind  with  high  affinity  to  MOR (Table 1)  [36, 
37, 41]. Also the endogenous opioid-like substance, nociceptin, is the product of a 
novel gene distinct from the gene families from which the classical endogenous opioids 
are derived (Table 1) [37]. In the CNS, opioids regulate nociceptive pathways both at 
spinal and supraspinal levels. At the spinal level, opioids inhibit nociceptive 
transmission conveyed by Aδ- and C-fibers [36]. 
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 Nonetheless, at the spinal cord, dynorphins have been associated with the 
development of hyperalgesia  and  allodynia  since  it  increases  the  release  of  
excitatory  neurotransmitters,  which contribute to intensify pain transmission [17, 36]. 
At the supraspinal level, opioid peptides inhibit ON-cells and disinhibit OFF-cells [35]. 
In  the PAG, enkephalinergic neurons synapse with serotoninergic neurons in the RVM 
that project to the spinal cord inducing the release of enkephalins that produce 
inhibition of the activity of Aδ- and C- ﬁbers entering the spinal cord [35, 36]. 
Noradrenergic cells from locus coeruleus projecting to the spinal dorsal horn are also 
regulated by the opioidergic system [35]. 
 The DRt is under opioidergic modulation since it expresses MOR and DOR [40, 
43]. As to the effects of opiods at this area the overexpression of proenkephalin at the 
DRt induced analgesia revealing thus that the effects of these opioid peptides inhibit 
DRt descending facilitacion of pain [44].  
 
3. Opioid-induced hyperalgesia 
  
 3.1. Definition  
 
 It is well know that the use of opioids may be a double-edged sword [34].They 
provide straight analgesic and antihyperalgesic effects but, the knowledge that opioids 
might have pronociceptive effects might have been suspected as early as the American 
Civil War [45]. Opioids have several side effects such as the development of physical 
dependence, tolerance and addiction [46, 47]. Nowadays there is an increased number 
of evidences that opioids may cause another phenomenon often referred to as opioid-
induced hyperalgesia (OIH) [45, 46]. This phenomenon is characterized by increased 
sensitivity to pain related to opioids exposure in the absence of disease progression or 
opioid withdrawal [34, 45-47]. 
 OIH definition is often mistaken with opioid tolerance and withdrawal-associated 
hyperalgesia (WAH). These syndromes can manifest similar symptoms, but are 
clinically differentiated from OIH due to differing effective interventions [48]. Tolerance 
occurs when the patient seeks pain relief and increasing doses of opioids are 
necessary to maintain appropriate analgesia (Figure 6 B) [48, 49]. This definition could 
be confused with OIH, however, in opposition to tolerance, increasing doses of opioids 
will only worsen pain (Figure 6 A) [46].  
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Figure 6:  Alterations in opioid dose-response relationship with chronic opioid administration. It is a hypothetical 
experience, where an acute opioid infusion is used to detect changes in the analgesic dose-experimental pain response 
curve that occur as a result of chronic opioid exposure. The responses of opioid naïve patients are shown as a solid 
line. A, In OIH, the dose-response curve of the chronic opioid user (dashed line) is shifted downward. B, In analgesic 
tolerance, the slope of the dose-response curve of the chronic opioid user (dashed line) becomes attenuated and  
rightward shifted, but, there is no significant change in pain sensitivity at baseline Adapted from Chu et al [50]. 
 
 WAH is a time limited reaction, translated as a diffuse joint pain and body aches  
taking place along with detoxification  from chronic opioid use or if scheduled doses are  
skipped [48]. 
 
3.2 Clinical and animal evidence 
 
 Several studies suggest that humans, as well as animals, treated with opioids 
can develop OIH. In humans the development of OIH already showed important clinical 
implications [34, 50]. Studies have been conducted using several distinct 
methodologies namely: former  opioid  addicts on methadone maintenance therapy; 
intraoperative exposure to opioids in patients undergoing surgery; healthy volunteers  
after acute opioid exposure; and prospective observational studies in opioid-naïve  pain 
patients undergoing initiation of chronic opioid therapy [34, 50]. 
Diverse clinical studies have measured pain sensitivity in former opioid addicts, treated 
with methadone, and this set of patients are compatible with the hypothesis that OIH, 
when diagnosed, is caused by chronic opioid exposure [34, 51]. Evidences that 
patients exposure to higher doses of intraoperative opioids increased postoperative 
pain is also compatible with the view that OIH developed in these patients [34, 52].  
There are also studies describing OIH in human volunteers after acute short-term 
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exposure to opioids and the results showed aggravation of induced hyperalgesic skin 
lesions, expansion of the area of mechanical hyperalgesia induced by transdermal  
electrical stimulation, aggravation of pressure-evoked pain or increased sensitivity to  
cold pressor pain in healthy human volunteers following precipitated opioid withdrawal 
after induction of acute physical opioid dependence [34, 50]. 
 A few clinical studies also show evidences of the development of OIH. A small  
prospective study in which OIH was notable in  6  patients  with  chronic  back  pain,  
after  one  month  of  oral  morphine  treatment,  when  compared to baseline values 
[49, 53]. Another research,  with a larger sample population, showed  a  significant  
negative  correlation  between  experimental  OIH  and  all  clinical  pain  measures, in 
a dose dependent manner [53]. One additional prospective study, with indirect 
evidence of OIH, comes from patients with chronic pain receiving intermediate-term 
opioid treatment who attended a pain rehabilitation program, which included the 
cessation of opioid use. Heat pain thresholds were increased at the end of the program 
compared to their levels prior to enrolment [53, 54]. 
 The first time OIH was described in animals was 1971 [55] and now more than 
a hundred publications are available describing this phenomenon in an extensive 
diversity of animal models [50]. For more than three decades,  it has been recognized  
that systemic exposure of opioids to rodents can lead to a hyperalgesic response after 
precipitating withdrawal with the administration of an opioid antagonist as well as  
during spontaneous withdrawal after cessation of opioid administration [34]. 
 Chronic administration of opioids also was shown to cause a sustained 
pronociceptive response. In these experiments, OIH depended both on the dose of the 
opioid and on the experimental pain model (i.e. thermal, mechanical, electrical or 
chemical) [48]. Two fundamental patterns characterizing the onset and resolution of 
OIH in animals can be distinguished. The first is observed after acute administration,  
that is, the systemic administration of one to four relatively high opioid doses within one 
hour, evoking a transient hyperalgesic response which lasts for hours or for days in a 
dose dependent manner [34]. The second and most common pattern is observed after 
animals are exposed to opioids on a chronic time course for three to twelve days via 
repeated subcutaneous injections, implantation of subcutaneous opioid containing 
pellets or pumps, or intermittent administration or continuous infusions through 
indwelling intrathecal catheters. If animals were exposed to opioids by continuous 
techniques, antinoceptive response is usually reported in the first day and then a loss 
of this effect is observed or along with the induction of a hyperalgesic state during 
ongoing drug administration. Alternatively, if animals receives repeated systemic or 
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intrathecal boluses of opioids for several days, they progressively develop hyperalgesia 
to thermal or mechanical stimuli. When studied, it was also possible to directly correlate 
the time course of resolution of OIH with the time course of its development [34]. 
 
3.3 Molecular mechanisms  
 
 The precise molecular mechanism of OIH are not yet well understood but, is  
thought to result from neuroplastic changes in the PNS and in the CNS resulting in  the 
sensitization of pronociceptive pathways and it can been described based on the site of 
the plasticity [19], where the relevant mechanisms are probably unique [50]. Spinal 
cord plasticity underlying OIH has been demonstrated after both intraspinal and 
systemic administration of opioids [19, 34, 50]. The consequence of spinal  
sensitization is increased transmission of noxious inputs to supraspinal sites [17]. It  is 
well accepted that repeated excitation of spinal cord neurons, along with persistent 
activation of the NMDA receptors, non-NMDA  excitatory amino acid  receptors, protein 
kinase C (PKC) [19, 34, 50], spinal dynorphin, spinal prostaglandins [34] and spinal 
cyclooxygenase (COX) [19] are involved in the sensitization of spinal neurons. The 
spinal dorsal horn is vital to many mechanisms supporting OIH [19], as the correlation 
between OIH and spinal cord plasticity is consonant with the emerging appreciation of  
spinal  inflammation as participating in many abnormal pain syndromes [19, 34, 50]. 
 Regarding the molecular mechanisms underlying OIH, there are evidences 
suggesting that after morphine binding to MOR, on a post-signaling neuron, there is 
activation of G-protein mediated PKC translocation and the removal of the NMDA 
receptor Mg2+ plug (Figure 7 – item 1). Glutamate is released from pre-synaptic cells  
inducing the ionotropic NMDA receptor to allow Ca2+ influx, resulting  in increased  
intracellular  Ca2+ which  leads  to  several  downstream  effects,  including  activation  
of  calcium-calmodulin (Ca2+-CaM), changes in gene expression and further activation 
of  PKC (Figure 7 – items a-b-c). Ca2+-CaM in turn initiates the conversion of L-arginine 
into nitric oxide (NO) by NO synthesis. NO may then act as a retrograde messenger to 
enhance glutamate release from the pre-synaptic neuron. With continual activation of 
these pathways, by opioid receptor occupation, PKC may uncouple the G-protein from 
MOR preventing any downstream signalling upon ligand binding [56]. There are also 
evidences suggesting that this process is not limited to neuronal cells and that glial 
cells also play an important part in OIH. Chronic opioid administration may  act  through 
MOR expressed on glial  cells  increasing  the  production  and  release  of  cytokines 
and chemokines or act directly on glial and neuronal glutamate transporters  to alter 
synaptic glutamate levels (Figure 7 - items 2 and 3). Once released, cytokines may 
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then act on the pre- or post-synaptic neurons to induce hyperalgesia or on other glial 
cells to promote further neuroimmune activation [56]. 
 
 
 
Figure 7: Cellular mechanisms of morphine hyperalgesia. Morphine (represented by M, as a representative opioid) may 
act on the post-synaptic neuron (1), on the glial cells (2) or on the pre-synaptic neuron (3). Regarding the post-synaptic 
neuron (1), it binds to the μ-receptor (μ-R) activates G-protein mediated protein kinase C (PKC) translocation and 
activation promoting removal of the Mg 2+  plug from the NMDA receptor (NMDA R). Glutamate (glu) released  from the 
pre-synaptic cells induces NMDA-R to allow Ca 2+ influx, increasing intracellular Ca 2+  which will result in the  activation 
of Ca 2+- CaM(calcium-calmodulin) (a), changes in gene expression (b) and further activation of PKC (c). Ca 2+ - CaM in 
turn initiates the conversion of L-arginine to NO mediated by nitric oxide synthase (NOS), which will enhance glutamate 
release from the pre-synaptic neuron. Chronic opioid administration also affects the μ-R on glial cells (2),  causing  an  
augmented  production  and  secretion  of  cytokines  and  chemokines  and  the  neuronal  glutamate  transporters 
(GluT) to alter synaptic glutamate levels (3). Abbreviations in figure not presented in text: G = G-protein  coupled to 
receptor; NO = nitric oxide; NMDA = N-methyl- D-aspartate Adapted from Deleo et al [56]. 
 
 The influence of higher CNS centres in OIH is yet poorly studied, however, 
there has been an increase in proven influence of supraspinal sites through enhanced 
descending facilitation to the spinal cord dorsal horn. So far, only the involvement of 
RVM was more deeply studied for OIH [19, 34, 50]. 
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3.4 cAMP response element binding protein (CREB) in OIH 
 
 CREB is a member of a superfamily of proteins that function as transcription 
factors and is expressed in all cells in the brain [57, 58]. Phosphorylation and 
successive activation of CREB is a site of convergence for several signal transduction 
cascades, including the cAMP pathway via protein kinase A (PKA), intracellular Ca2+ 
via Ca2+-calmodulin-dependent kinases (CaMK), the Ras/ extracellular signal regulated 
kinase (ERK) protein kinase pathway, the phosphotidylinositol-3-kinase (PI3K)/ Akt 
kinase pathway, PKC pathways and stress-induced signaling cascades [58-60]. 
 CREB is of particular interest since its activation is downstream of the cAMP 
signaling pathway, whose upregulation has been widely characterized as an adaptation 
to opioid chronic exposure [58]. Generally when morphine binds to MOR, adenylyl 
cyclase (AC) is inhibited and in consequence cAMP decrease and reduces the 
phosphorylation of CREB (pCREB) however, chronic opiate administration, increases 
levels of AC and pCREB implying a homeostatic or compensatory regulatory 
mechanism. This increased CREB activity appears to play an important role in physical 
opiate dependence and withdrawal [58, 61-63].  
 Several experimental evidences suggests that pCREB is involved in the opioid-
induced effects in vitro and in vivo, beginning in cultured neuronal cell lines and 
extending to several brain areas [64].  In vitro it was shown that chronic administration 
of morphine increase pCREB in the coeruleus-like cell line [65]. In vivo it was shown 
that chronic administration of morphine increase pCREB in the locus coeruleus (LC) 
[58, 61, 66] or in the nucleus accumbens (NAc) [58, 67, 68]. Also mice containing 
targeted mutations on α and Δ isoforms of CREB gene showed attenuated physical 
symptoms of morphine withdrawal [58, 69]. The knockdown of CREB levels in the LC, 
using antisense oligonucleotides, blocks the capability of chronic opiates to upregulate 
some components of the cAMP pathway and consequently blocked some of the effects 
of morphine like physical dependence and withdrawal [62]. Similar results were 
observed when increasing or decreasing CREB levels in the LC using viral vectors [61]. 
 A remaining mystery, however, is the exact mechanism which opiate exposure 
switches from acute inhibition of the cAMP pathway and CREB to chronic upregulation 
[61]. 
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4. Opioids and reward 
 
 Reward is defined as a stimulus that brain interprets as intrinsically positive or 
as something to be approached [70]. Usually, rewards are conditionally learned based 
upon their positive influence on survival or reproduction [71, 72]. 
 Pain and reward are opposite processes that can interact and inﬂuence each 
other. Some rewarding stimuli decrease pain sensitivity but on the other hand it  has 
been proved that pain affect reward processing [73]. For example, chronic pain is 
associated with anhedonia, i.e. the incapacity to feel pleasure. Several brain systems 
are implicated in pain and reward processing such as the amydala, anterior and 
posterior insula, anterior cingulate cortex, dorsal and ventral striatum and the 
orbitofrontal cortex [73, 74]. 
 Dopamine is a key neurotransmitter of reward [73, 75]. This catecholamine is 
released from the ventral tegmental area (VTA) that project mainly to the NAc and the  
prefrontal cortex (PFC) as a result of natural rewarding experiences, such as eating 
[71, 76] or in response to administration of drugs of abuse such as cocaine, 
amphetamine, opiates, nicotine and alcohol [71, 77, 78]. Although the dopaminergic 
system represents the cornerstone of the reward system other neurotransmitters, such 
as endogenous opioids, affect this mesolimbic dopaminergic system [72].  
 The opioid system represents an important substrate for the prejudicial effects 
of drugs of abuse. As a matter of fact activation of MOR reinforces the properties of 
countless abused drugs, which may be a potential molecular gateway to drug addiction 
[79, 80].  Van Ree et al [81] in 1980 was the ﬁrst to demonstrate that rats self-
administer an opioid receptor agonist into the VTA. Since then, several studies using 
intracerebral self-administration or conditioning place preference (CPP) in rats have 
conﬁrmed the contribution of the VTA in opiate reinforcement [79, 82, 83]. More 
recently, genetic approaches using knockout animals have conﬁrmed the role of opioid 
system in drug reinforcement and dependence [79]. Constitutive knockout mice for 
MOR, DOR and KOR have been used to study reward processes [70]. Several 
researches demonstrated an essential role of MOR in facilitating reward. Opiate reward 
studies in MOR knockout mice showed a loss of morphine reward on CPP as well as 
morphine self-administration test [70, 84, 85]. The DOR influence on reward is less 
evident. The analysis of DOR knockout animals showed a decreased morphine place 
preference but morphine self-administration was maintained, suggesting that this opioid 
receptor contribute to contextual learning rather than opioid reward [70, 79]. 
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In addiction a large number of studies using KOR knockout mice confirm that this 
receptor negatively modulates reward, although this is not shown for all drugs of abuse, 
for example deletion of the KOR gene did not modify morphine CPP but in contrast 
reduced alcohol place preference [70, 79]. 
 Chronic exposure to opioids, or another drugs of abuse enhance the activity of 
the cAMP–PKA pathway in NAc. Activation of PKA and subsequent phosphorylation of 
CREB within Nac reduces the rewarding effects of stimulant drugs, whereas PKA 
inhibition has the opposite effect [86]. Indeed, elevation of CREB levels within the rat 
NAc using viral vectors reduce the rewarding effects of morphine and cocaine and 
make low doses aversive, suggesting that CREB activity in this region can control 
reward qualities of drugs of abuse [57].  
 
 5. Genetic manipulation of the nociceptive system 
 
 Conventional drug treatment for pain has numerous limitations, such as drug 
dependence, tolerance, respiratory depression, and other systemic side effects [87]. 
The development of gene transfer has a possibility of using nonviral or viral vectors to 
transduce genes encoding antinociceptive substances to treat chronic pain and study 
the nociceptive system [87, 88]. 
 An ideal delivery system would transduce cells with high efficiency, mediate 
high level  and  long-term  expression,  cause  limited  cytotoxicity,  produce  a  small 
immune  response in vivo and incorporate sufficient DNA so that transgenes of interest 
can be accommodated and enable regulated expression. These characteristics are 
difficult to achieve in a single vector system consequently, a variety of viral gene 
delivery systems have been developed, each with its own advantages and 
disadvantages [89]. Nonviral systems, like naked DNA or RNA, liposomes and 
nanoparticles, compared with viral vectors are less efficient since viral vectors are more 
capable of delivering exogenous genes to target cells and inducing long-term gene 
expression [87, 88]. 
 In recent years, the development of selective genetic manipulation has largely 
enriched the understanding of molecular mechanisms of the descending pain 
modulatory system [13, 90]. Pre-clinical trials of gene therapy for pain control reporting 
promising results, related to safety and efficacy, along with an early clinical trial with 
exciting outcomes show the potential of the genetic manipulation of the nociceptive 
system [44, 91, 92]. All knowledge acquired on the mechanisms of pain, allowed  to 
develop vectors carrying transgenes with specific promoters directed to  targets  of  the  
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CNS  and  of  the  PNS  deeply  involved  in  facilitation  of  pain  and  somatosensory  
system  areas  [13]. Thereby, gene transfer allows the delivery or manipulation of 
genes with high specificity, avoiding side effects and off- target toxicity, mediating gene 
expression for a controlled and prolonged period of time [93]. The greater advantage of 
gene therapy is that this system is readily controllable. There are three main 
components that can be manipulated: the vector, the transgene and the promoter [13]. 
The vector is the carrier of the transcriptional cassette and its main function is to deliver 
its content to specific cell targets. Some of the viral vectors have the ability to be 
transported retrogradely, which allows the vector to be uptaken at the nerve terminal 
and then migrate to the nucleus, often located in remote areas, surgically difficult to 
access [13]. The most commonly used viral vectors for gene therapy for chronic pain 
are derived from the herpes-simplex virus (HSV-1), adeno-associated virus, adenovirus 
and lentivirus due to some characteristics, such as their low immunogenicity, natural 
integration ability and whether they can infect both dividing and nondividing cells [87, 
91]. 
 Lentiviral vectors belong to a subclass of retroviruses capable of inserting DNA 
into the host cell genome. They are interesting vectors due to their natural integration 
ability and tropism for non-dividing cells such as neurons. They have also been used 
for gene delivery in neural stem cells and progenitor cells [87]. 
 The transgene is a coding sequence of a gene which can be fused with small 
unrelated  sequences  or  even expressed  under the  same promoter  with  fluorescent 
proteins,  so  cells  transfected  with  the  transgene  can  be  easily  detected  [93]. 
These coding sequences generally express antisense sequences or RNAi molecules in 
order to down-regulate gene expression [93], or neurotransmitters and receptors 
involved in pain transmission, neurotrophic factors and anti-inflammatory substances 
[13].   
 As for the promoter, cell-type specific promoters are preferred in order to restrict 
gene expression to a specific cell type. Synapsin I, calcium/calmodulin-dependent 
protein kinase II, tubulin alpha I and neuron-specific enolase are some examples of the 
promoters specifically targeting neurons [13]. 
 Targeting brain circuits of pain is definitely challenging mainly because the 
access to brainstem areas is a great obstacle and the complex neuronal circuits are 
also difficult to manipulate. Gene transfer in the endogenous pain control system has 
been  mainly  achieved  with  HSV-1  vectors  to  express  opioid  peptides  [92] 
glutamate  decarboxylase (GAD) [94] and tyrosine hydroxylase [28] inducing analgesia 
in several  pain models [13, 40, 44, 92].   
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Aims and methodology 
 
 The analgesic role of opioids for the treatment of chronic pain is of extreme 
importance, since chronic pain afflicts a large amount of people worldwide. 
Nonetheless, chronic opioid administration may lead to several side effects, including a 
paradoxical hyperalgesic effect, also known as opioid-induced hyperalgesia (OIH). 
Several evidences suggest that descending facilitatory pathways are involved in the 
modulation of OIH.  The  dorsal  reticular  nucleus  (DRt)  exerts  a  unique  role  in  
descending  pain  facilitation and its activity is modulated by opioids. 
 The first goal of the present thesis was to determine the behavioural effects of 
chronic morphine administration in naïve animals and in a chronic pain model, the 
spared nerve injury (SNI), which is a model that presents substantial and prolonged 
changes in mechanical sensitivity and thermal responsiveness that mimic several  
features of clinical neuropathic pain [95]. First we assessed the effects of chronic 
administration of morphine on pain behaviors then on the reward effects of morphine. 
We used the von-Frey test by to evaluate mechanical allodynia and the hot plate test to 
verify changes in thermal hyperalgesia in naïve animals. Pain assessment in SNI 
animals was performed using the von-Frey test to assess mechanical allodynia, the 
pin-prick test to verify changes in mechanical hyperalgesia and the acetone test to 
study cold allodynia. To study reward behavior we used the conditioned place 
preference (CPP) test which is an established rodent paradigm of drug reward [96]. 
First, we performed the optimization of the different experimental conditions involved in 
the test. Then, we performed the CPP test to evaluate the effects of chronic morphine 
treatment in morphine reward. 
 The second aim of this thesis consisted on studying the involvement of the DRt 
in chronic morphine effects. For that, first we evaluated the effects of DRt inactivation 
by local injection of lidocaine on chronic morphine pain behavior, by the behavioural 
tests described above in naïve animals. Then we studied the effect of chronic morphine 
on the expression of the phosphorylated cAMP response element-binding protein 
(pCREB) and  opioid receptor (MOR) by immunohistochemical detection, at the DRt.  
Additionally, we evaluated the effects of MOR knock-down at the DRt in naïve and SNI 
animals using a lentiviral vector. This  vector  was  chosen  since it  does  not  undergo  
retrograde  transport  and , unlike other viral vectors, only transduce on local neurons 
[97]. We determined the effects of MOR knock-down on pain behaviour during chronic 
morphine administration. We also evaluated the effects of MOR knock-down to assess 
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the involvement of the DRt, in reward during chronic morphine administration. MOR 
knock-down was confirmed by immunohistochemical analysis. 
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Materials and Methods 
 
1.  Animals 
 Pathogen-free adult male Wistar rats (Charles River colony, France) were pair-
housed in standard Plexiglas cages with free access to food and water. After 
stereotaxic injections, the animals were housed individually. The colony room was 
maintained at 22 ± 2°C on a standard 12/12h light/dark cycle. All experiments were 
conducted during the light phase. Upon arrival, rats were allowed five days of 
acclimation before any procedure. All procedures were performed in accordance with 
the European Community Council Directive (2010/63/EU) and the ethical guidelines for 
pain investigation (Zimmermann, 1983).  
 
2. Lentiviral vectors 
 The lentiviral vectors used in this study were kindly provided by Professor 
Steven Wilson from the University of South Carolina (Dpt. of Pharmacology, Physiology 
and Neurosciences). 
 We used a lentiviral vector that knocks down MOR expression (MOR-R, Figure 
8) carrying the human synapsin promoter (hSYN-p), MOR cDNA in reverse orientation 
and the enhanced green fluorescent protein (EGFP) cDNA. The control vector (LV-
Cont; Figure 8) only carries the EGFP transgene. The vectors further carry the 
encephalomyocarditis virus internal ribosome entry site (IRES) and transcriptional 
regulatory element (WPRE). 
 The lentiviral particles were produced by co-transfection of human embryonic 
kidney β9γT cells with the lentiviral vectors, a packaging plasmid (pCMVΔR8.9β), a 
plasmid encodingthe rev protein (pRSV-Rev) and a plasmid encoding the vesicular 
stomatitis virus G glycoprotein (pMD.G). The vectors were titrated by quantitative real-
time PCR and stored in 10% sucrose in PBS (Appendix A). 
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Figure 8: Schematic diagrams of the vectors. The lentiviral vectors contain the human synapsin promoter (hSYN-1p), 
the coding region of EFGP vector (LV-Cont) or MOR cDNA in reverse orientation (MOR-R vector). The  vectors  further  
carry  the  encephalomyocarditis  virus  internal  ribosome  entry  site  (IRES)  and  the transcriptional regulatory 
element (WPRE). Abreviations: LTR- long terminal repeat. 
3. Surgical procedures 
 
3.1. Osmotic mini-pump implantation 
 Mini-osmotic pumps (ALZET-model 2001- 200L; figure 9) were filled with 
saline or morphine (45 g-1. L-1.h-1), and immersed in a 0,9% saline solution at 37ºC 
for at least 4 hours before implantation, for stabilization purposes.      
  
 
 
Figure 9: Schematic representation of a osmotic mini-pumps. These mini pumps act by osmotic pressure differences 
between their interior side (osmotic layer) and the tissue where the mini-pump is implanted. The higher concentration of 
the osmotic layer constituents triggers the entrance of water to the mini-pump through a semi-permeable membrane 
covering the surface of the mini-pumps. As water comes in, the osmotic layer compresses the flexible compartment 
releasing the agent previously packaged inside the reservoir. The flow is determined by the exterior membrane 
permeability, by the temperature (which should be around 37ºC) and by the osmolatily. 
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 Animals were anesthetized with isofluorane (IsoFlo®) and their dorsum was 
shaved and cleaned with Betadine® solution. A midline incision was made in the skin 
and with a blunt-pointed scissors the skin was separated from the fascia and pumps 
were implanted subcutaneously (Figure 10). The incision was closed with surgery 
staples (Stoelting®, U.S.A.) and animals returned to their home cage. 
 
 
 
Figure 10: Implant of the mini-pumps in animals dorsum. 
 
 The animals were monitored daily to evaluate body weight and to detect 
withdrawal signs caused by incorrect functioning of the mini-pumps such as teeth 
chattering, diarrhea, rhinorrhea, ptosis, irritability, lacrimation, escaping, penile erection 
and abnormal posture [98]. 
 
 
3.2. Neuropathic pain induction  
 
 The neuropathic pain model Spared Nerve Injury (SNI) was induced as 
described by Decosterd and Woolf [95]. First, rats were administered intraperitoneally 
(i.p.) with a mixture of ketamine hydrochloride (Imalgene 1000®- 0,06 g/Kg) and 
medetomidine (Medetor®- 0,25 g/Kg). Then, the left thigh of the animals was shaved 
and disinfected with Betadine®, the skin was incised vertically approximately 3,5 cm 
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and, using a blunt-pointed scissors, a section was made directly through the biceps 
femoris muscle exposing the sciatic nerve and its three terminal branches: the common 
peroneal (Fig. 11, item 1), tibial (Fig. 11, item 2) and sural (Fig. 11, item 3) nerves. 
 
 
 
Figure 11: Exemplificative picture of the terminal branches of sciatic nerve. (1) common peroneal, (2) tibial (3) sural 
nerves. 
 
 
 The SNI procedure comprised the axotomy and ligation of the tibial and 
common peroneal nerves leaving the sural nerve intact. The common peroneal and the 
tibial nerves were isolated from the sciatic nerve, tight-ligated with 4.0 silk and 
sectioned distal to the ligation, removing 2 ± 4 mm of the distal nerve stump, preventing 
nerve regeneration. During the procedure, the sural nerve was carefully maintained 
intact. After the procedure, the muscle was sutured with 4.0 silk and the skin was 
sutured with surgery staples (Stoelting®, U.S.A.). All animals were rehydrated by 
subcutaneous (s.c.) administration of saline solution 0,9% and the anaesthesia was 
reverted with a s.c injection of atipamezole hydrochloride (Revertor®- 0,5 g/Kg). The 
staples suturing the skin were removed approximately 7 days after surgery. 
 Mini-pump implantation or mini-pump implantation in simultaneous with 
stereotaxic surgeries were performed between 2 to 3 weeks after SNI induction. This 
timing was chosen because after that period pain behaviours were shown to be robust 
and stable [28, 95]. 
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3.3. Stereotaxic surgeries 
 Stereotaxic surgeries were performed for cannula implantation and lentiviral 
vectors injection into the left DRt of animals weighing 285-315g. 
 
3.3.1 Cannula implantation 
 
 Naïve animals were deeply anesthetized by an i.p injection of a mixture of 
ketamine hydrochloride (0.06 g/Kg) and medetomidine (0.25 g/Kg). The animals were 
placed on a stereotaxic frame (David Kopf Instruments, U.S.A.) by positioning their 
head in the incisor bar (figure 12 B) and insertion of earbars into each ear canal(figure 
12 C). Once each earbar was inserted, verified by a blink reflex usually induced by the 
contact of the earbar with the ear canal, the rat was placed into the holder and fixed. 
The head of the animal was cleaned with Betadine® solution and using a scalpel, a 
midline incision was made to separate the muscle and fascia, to expose the bone. 
Then four small burr holes were drilled, one over the left DRt and the other three in the 
surrounding area in order to implant screws to support the guide cannula (Plastics 
One® C315G Guide 266A 38172 11MM). The coordinates to target the left DRt, shown 
in Table 1, were determined according to the rat brain atlas relative to the interaural 
line. The interaural line was used as a reference to calculate the coordinates (Figure 
13). The guide cannula was lowered (figure 12 A) until its tip was 3 mm above the DRt 
and was immobilized using a self-polymerizing acrylic (Vertex™ Self-Curing). A dummy 
Cannula (Plastics One®-Fit 11 MM C 315G W-O) was placed in the guide cannula to 
prevent its obstruction. At the completion of the stereotaxic procedure, the animals 
were implanted with osmotic mini-pumps filed with morphine (45µg-1.µL-1.h-1) (n = 6) or 
saline (n= 7). The animals were rehydrated by subcutaneous (s.c.) administration of a 
saline solution 0,9% and the anesthesia was reverted with an s.c. injection of 
atipamezole hydrochloride (Revertor®-0,5 g/Kg). The animals were individually housed 
and monitored daily to evaluated body weight, and visible motor deficit and sedation. 
One week after cannula and mini-pumps implantation, a volume of 0.5μl of lidocaine at 
4% was injected through the guide cannula and the behavioral effects of lidocaine were 
tested before and 30 min after injection (Scheme 2). 
 A guide cannula was also implanted into the left VLM (n = 3) or left Sol (n = 3) in 
order to verify that the effect of lidocaine was not the result of lidocaine spreading to 
surrounding areas of the DRt. The coordinates to target the left VLM and left Sol are 
shown in Table 2. At the completion of the stereotaxic procedure, the animals were 
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implanted with osmotic mini-pumps filed with morphine and 0.5μl of lidocaine at 4% 
was injected through the guide cannula as described above. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: The stereotaxic frame. (A) cannula support, (B) Incisor bar and (C) earbars. 
 
 
Figure 13:  Dorsal view of the rat skull. Position of the interaural  line  used  as  a  reference  to  calculate  the  
coordinates to target the DRt. The positions of bregma and lambda points are also shown in the diagram. Bregma and 
lambda are used as references to calculate coordinates to target rostral brain regions. Adapted from Paxinos and 
Watson [30]. 
 
A 
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Table 2: Stereotaxic coordinates to target the left dorsal  reticular  nucleus (DRt), caudal ventromedial medulla (VLM) 
and Solitary nucleus (Sol) for implantation of a guide cannula. 
 
Cordinates (mm) 
 
Area 
↓ 
AP (Anterior-
posterior) 
LM (Latero-
medial) 
DV (Dorso-
ventral) 
Left  DRt -6,0 +1,4 -1,5+3 
Left VLM −5.8 −2.2 −2.6+3 
Left Sol −6.0 mm −0.8 mm −1.2+3 
 
3.3.2 Vectors injection 
 
 Stereotactic injections were performed to inject lentiviral vectors into the left DRt 
of naïve and neuropathic animals (2-3 weeks after SNI induction). Rats were deeply 
anesthetized by an i.p injection of a mixture of ketamine hydrochloride (0.06 g/Kg) and 
medetomidine (0.25 g/Kg) and placed on a stereotaxic frame as explained above. The 
head of the animal was cleaned with Betadine® solution and using a scalpel, a midline 
incision was made to separate the muscle and fascia, to expose the bone. Then a 
small burr hole was drilled over a targeted area and, with a blunt needle, the dura was 
carefully pierced. Using a Hamilton syringe the rats received two injections of the 
control vector (LV-Cont; naïve animals n = 11; SNI animals n = 11) and MOR-R (naïve 
animals n = 11; SNI animals n = 12) at a volume of 0.6 l each injection at 5.106 TU1/l 
in two different rostrocaudal locations of the DRt following the stereotaxic coordinates 
shown in Table 3. The lentiviral suspensions were injected at the slow rate (0.2 l/2 
min) and, at the completion of each injection, the needle was left in place for 10 min to 
avoid reflow, before being slowly removed. At the completion of the stereotaxic 
procedure, the animals were implanted with osmotic mini-pumps filled with morphine 
(45 µg-1.µL-1.h-1) or saline. The animals were rehydrated by s.c. administration of a 
saline solution 0.9% and the anesthesia was reverted with a s.c. injection of 
atipamezole hydrochloride (Revertor®-0.5 g/Kg). The animals were then individually 
housed and monitored daily to evaluated body weight, and any visible motor deficit and 
sedation. The effects of the lentiviral vectors were behaviorally tested one week after 
stereotaxic surgery and mini-pump implantation (Schemes 3, 7).  
1 TU- Transducing units 
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Table 3: Stereotaxic coordinates to target the left DRt 
Cordinates (mm) Left DRt (1st injection) Left DRt (2nd injection) 
AP (Anterior-posterior) -6,0 -6,4 
LM (Latero-medial) +1,4 +1,3 
DV (Dorso-ventral) -1,5 -1,7 
 
 
4. Behavioural analysis 
4.1. Nociceptive behavioural analysis 
 
4.1.1. Pain assessment in naïve animals  
 Pain assessment in naïve animals was performed using the von Frey and Hot 
plate tests which allow to evaluate mechanical allodynia and thermal hyperalgesia, 
respectively. The tests were performed after a period of habituation of one week, 
during which the animals were handled by the experimenter in the test room for 30 min 
every day and placed in the testing apparatus for another 30 min (Figure 14 A). The 
criteria for adequate habituation were that animals did not freeze or defecate when 
placed in the testing apparatus.   
 The von Frey test was performed by the "up and down" method. The rats were 
placed on an elevated transparent cage with a mesh wire bottom allowing the 
stimulation of the plantar surface of left hind paw with a series of von Frey 
monofilaments (Stoeling, U.S.A.) ranged between 0.41 to 15 grams (Figure 14 B). A 
positive response was noted if the paw was sharply withdrawn upon application of the 
filament. Flinching or licking immediately upon removal of the filament were also 
considered a positive response [99].  
 The hot plate test was performed by placing the rat on a hotplate (BIO-CHP 
Cold Hot Plate Test) system, with a surface temperature of 52ºC. A rectangular 
Plexiglas chamber (35 cm high) with a removable top was used to conﬁne the rat to a 
16.5 cm × 16.5 cm hotplate surface during testing (Figure 14 C). Nociceptive threshold 
was quantiﬁed as the latency (in seconds) to licking, retraction of the hind paw or jump 
(all paws simultaneously leaving the plate surface) after placement of the rat on the 
hotplate. All rats was removed from the hotplate after a 30-s cutoff to avoid tissue 
injury.  
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 These behavioral tests were used to evaluate: 
i) the time course effects of chronic morphine administration. For this, the animals 
were implanted with a mini-pump filled with morphine (45 µg-1.µL-1.h-1) or saline 
(n=6 each group; Scheme 1). Von Frey and Hot plate tests were performed before 
and at 2, 4 and 7 days after mini-pump implantation (Scheme 1); 
ii) the effects of DRt inactivation by lidocaine on chronic morphine administration. For 
this, two subsets of animals were used, as described above. One subset of 
animals was implanted with a guide cannula into DRt and with osmotic mini-pumps 
for the s.c. delivery of morphine (45 µg-1.µL-1.h-1) (n=7) or saline (n=6). The second 
subset of animals was implanted with off target cannulas and with osmotic mini-
pumps for the s.c. delivery of morphine (45 µg-1.µL-1.h-1; n=6). The behavioural 
tests were performed 7 days after guide cannula and mini-pump implantation 
before and 30 min after lidocaine injection through the guide cannula (Scheme 2);  
iii)  the effects of MOR knock down at the DRt on chronic morphine administration. 
For this, the animals were injected with lentiviral vectors at the DRt, as explained 
above, and implanted with mini-pumps for the s.c. delivery of morphine (45 µg-1.µL-
1
.h-1;LV-Cont n = 6; MOR-R n= 5) or saline (LV-Cont n = 5; MOR-R n= 6) as 
described above. The behavioural tests were performed before and at 2, 4 and 7 
days after lentiviral vectors injection and mini-pump implantation (Schema 3). 
  
 The time course effects of chronic morphine administration was analysed by 
two-way repeated measures of ANOVA followed by Tukey post-hoc test for multiple 
comparisons. The effects of lidocaine or lentiviral vectors injection into the DRt were 
analysed by two-way ANOVA followed by Tukey post-hoc test for multiple 
comparisons. The effects of lidocaine injection into the off-target sites were analysed 
by paired t tests. 
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Figure 14: Behavioural tests apparatus. (A)  Animal placed in the individual Plexiglas container in the wire grid; (B) von-
Frey test; (C) Hotplate test. 
 
 
 
 
 
 
 
Scheme 1: Time course effects of chronic morphine administration in naïve animals. Mini-pump implantation for the s.c. 
delivery of morphine (45 µg-1.µL-1.h-1) or saline was performed at Day 0. The animals were tested at Day 0 (Baseline; 
BL), before mini-pump implantation and at Days 2, 4 and 7 after mini-pump implantation. 
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Scheme 2: Effects of DRt inactivation by lidocaine on chronic morphine admnistration in naïve animals. Stereotaxic 
surgery for the implantation of a guide cannula and osmotic mini-pumps implantation for the s.c. delivery of morphine 
(45 µg-1.µL-1.h-1) or saline were performed at Day 0. The animals were tested at Day 7 before and after lidocaine 
injection through the guide cannula. 
 
 
 
 
Scheme 3: Effects of MOR knock down at the DRt on chronic morphine admnistration in naïve animals. The stereotaxic 
injection of the lentiviral vectors LV-Control and MOR-R and the implantation of osmotic mini-pumps for the s.c. delivery 
of morphine (45 µg-1.µL-1.h-1) or saline was performed at Day 0. The animals were tested before the surgical procedures 
at Day 0 and at Day7. 
 
4.1.2. Pain assessment in neuropathic animals  
 Pain assessment in neuropathic animals was performed by the von Frey, pin 
prick and acetone tests which allow to evaluate mechanical allodynia, mechanical 
hyperalgesia and cold allodynia, respectively. The tests were performed after a period 
of habituation of one week, during which the animals were handled by the experimenter 
in the test room for 30 min every day and placed in the testing apparatus for another 30 
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min. The criteria for adequate habituation were that animals did not freeze or defecate 
when placed in the test apparatus. 
 To perform the tests, the rats were placed on an elevated transparent cage with 
a mesh wire bottom allowing the stimulation of the lateral surface of the left hind paw 
(Figure 15). The von-Frey test was performed by applying von Frey monofilaments 
(Stoeling, U.S.A.) in a sequence of increasing stiffness for 5 seconds [100]. The 
threshold was taken as the lowest force that evoked a brisk withdrawal response to one 
of five repetitive applications (Figure 15 A). The pin prick test was performed by the 
application of a brief stimulation with a safety pin (Figure 15 B) at an intensity sufficient 
to produce a reflex withdrawal response but not penetrate the skin and the duration of 
paw withdrawal was clocked [101]. The acetone test was performed by application of 
40 µL of acetone using a micropipette tip connected to a micropipette without touching 
the skin (Figure 15 C) and the duration of the withdrawal was timed [102]. 
 
 
 These behavioral tests were used to evaluate: 
 
i) the time course effects of chronic morphine administration. For this, 2-3 weeks 
after SNI induction, the animals were implanted with a mini-pump filled with 
morphine (45 µg-1.µL-1.h-1) or saline (n=6 each group; Scheme 4). Von-Frey, pin-
prick and acetone tests were performed before and at 2, 4 and 7 days after mini-
pump implantation (Scheme 4); 
ii) the effects of MOR knock down at the DRt on chronic morphine administration. For 
this, 2-3 weeks after SNI induction, the animals were injected with lentiviral vectors 
at the DRt and implanted with mini-pumps for the s.c. delivery of morphine (45 µg-
1
.µL-1.h-1;LV-Cont n = 6; MOR-R n= 6) or saline (LV-Cont n = 5; MOR-R n= 6) as 
described above. The behavioural tests were performed before and at 2, 4 and 7 
days after lentiviral vectors injection and mini-pump implantation (Scheme 5). 
 
 The time course effects of chronic morphine administration and the effects of 
lentiviral vectors injection into the DRt were analysed by two-way ANOVA followed by 
Tukey post-hoc test for multiple comparisons. 
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Figure 15: Behavioural tests apparatus. (A) von-Frey test; B) Pin-prick test; (C) Acetone test. 
 
 
 
 
 
 
 
 
Scheme 4: Time course effects of chronic morphine administration in neuropathic (SNI) animals. Mini-pump implantation 
for the s.c. delivery of morphine (45 µg-1.µL-1.h-1) or saline was performed at Day 0, i.e. 2-3 weeks after SNI surgery. The 
animals were tested at Day 0 (Baseline; BL), before mini-pump implantation and at Days 2, 4 and 7 after mini-pump 
implantation. 
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Scheme 5: Effects of MOR knock down at the DRt on chronic morphine administration in neuropathic (SNI) animals. 
The stereotaxic injection of the lentiviral vectors LV-Control and MOR-R and the implantation of osmotic mini-pumps for 
the s.c. delivery of morphine (45 µg-1.µL-1.h-1) or saline was performed Day 0, i.e. 2-3 weeks after SNI surgery. The 
animals were tested before the surgical procedures at Day 0 and at Day7. 
 
 
4.2. Morphine reward behavioural analysis 
 
 The analysis of the reward behaviour was performed using the Conditioned 
Place Preference test (CPP). The CPP paradigm is a standard behavioural test used to 
study the rewarding and aversive effects of drugs. The test involves the association of 
a particular environment, through visual and tactile cues, with a drug treatment. This is 
known as the conditioning phase of the test. The conditioning phase is followed by a 
post-conditioning phase, during which the animals associate a different environment 
with a drug but in the absence of the drug [103]. A common variation of this design 
consists of a three-compartment chambers with two different conditioning 
chambers/contexts, distinguished by visual and sensory cues, to which the animal is 
exposed once or several times, that are connected by a neutral chamber, with no 
special characteristics and is not paired with a drug. Before the conditioning phase (i.e. 
during the pre-conditioning phase), the animal should not present a previous 
preference for any chamber/context [103, 104].  
 The CPP test was used for the first time in the laboratory therefore we first 
optimized the test. We tested different visual and tactile cues/contexts in order to obtain 
contexts towards which the animals present no preference before the conditioning 
sessions (i.e. during the pre-conditioning phase). We also tested the number of 
conditioning sessions, which is the number of conditioning trials/sessions the animal is 
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exposed to one of the different chambers/contexts during the conditioning phase. All 
experiments were performed using neuropathic animals 2 to 3 weeks after SNI 
induction. 
  
4.2.1. Optimization of visual cues 
 
 The optimization of the visual cues was performed in a Plexiglas apparatus 
measuring 100 [length (L)] X 40 [width (W)] X 40 [height (H)] cm and comprising two 
distinct conditioning chambers separated by a neutral chamber. The neutral chamber 
measured 20 X 40 X 40 cm with black Plexiglas walls. Each conditioning chamber 
measured 40 (L) X 40 (W) X 40 (H) cm and contained different visual clues. One 
chamber had walls with alternating 3 cm wide black and white horizontal stripes. The 
second chamber had alternating 3 cm wide black and white vertical stripes. The tactile 
cues were the same in the three chambers, which is all chambers, had black Plexiglas 
floors. 
 Rats (n = 5 were placed in the neutral chamber with full access to all chambers 
for 15 min for 2 consecutive days. Day 1 was used for habituation purposes. On day 2 
(pre-conditioning phase), rats behaviour was recorded for 15 minutes using a video 
camera. The time spend in each chamber was analysed by Ethlog 2.2. 
 
4.2.2. Optimization of tactile cues 
 
 The optimization of tactile cues was performed in a Plexiglas apparatus with the 
characteristics described above. The visual clues in the conditioning chambers were 
the ones tested above. The following tactile textures in the floor of each conditioning 
chamber were tested: 
1- Mesh wire floor in one chamber / Black Plexiglas floor in the other chamber; 
2- Mesh wire floor in one chamber / Corn cob in the floor of the other chamber; 
3- Mesh wire floor in one chamber / Metallic floor with 0.5 cm diameter circles spaced 
1 cm in the other chamber; 
4- Mesh wire floor in one chamber / 0.5 cm diameter metal rods spaced 2 cm in the 
other chamber. 
 Rats (n = 15) were placed in the neutral chamber with full access to all 
chambers for 15 min for 2 consecutive days. Day 1 was used for habituation purposes. 
On day 2 (pre-conditioning phase), rats behaviour was recorded for 15 minutes using 
a video camera. The time spend in each chamber was analysed by Ethlog 2.2. 
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4.2.3. Optimization of the number of conditioning trials/sessions. 
 
 The optimization of the number of conditioning sessions was performed in a 
Plexiglas apparatus with the dimensions described above and with visual and tactile 
cues that showed unbiased pre-conditioning results. One chamber of the CPP 
apparatus had a floor with 0.5 cm diameter metal rods spaced 2 cm and walls with 
alternating 3 cm wide black and white horizontal stripes. The floor of the second 
chamber was a mesh wire and the walls had with alternating wide black and white 
vertical stripes.  
 We tested the effect of morphine (10 mg/Kg) on a single and a multi-trial 
conditioning protocol.  
 Rats were placed in the neutral chamber with full access to all chambers for 15 
min for 2 consecutive days, Day 1 was used for habituation purposes and on day 2 
(pre-conditioning phase), rats behaviour was recorded for 15 minutes, as explained 
above. Rats spending less than 20% or more than 80% of the entire time in one of the 
chambers were excluded. Each rat was then randomly assigned to a treatment group 
and a conditioning chamber/environment in a counterbalanced fashion. 
 During the conditioning phase, Plexiglas partitions matching their respective 
environments were inserted to restrict the rats to a specific designated 
chamber/environment. In the single-trial conditioning protocol (n = 3), on Day 3 the 
animals, were subcutaneously injected with saline and randomly placed in a 
conditioning chamber for 1 hour. Four hours later, the animals were subcutaneously 
injected with morphine (10 mg/Kg) and placed in the other chamber for 1 hour. In the 
multi-trial conditioning protocol (n = 3), the animals were conditioned on Days 3-8. The 
animals were subcutaneously injected with saline or morphine (10 mg/Kg) once a day 
on alternate days. The animals were placed into the designated conditioning chamber 
for 1 hour immediately after the injection. 
 On post-conditioning day (Day 4 in the single single-trial conditioning protocol; 
Day 9 in the multi-trial conditioning protocol), rats were placed in the neutral chamber in 
a drug-free state, with access to all chambers, their behaviour was recorded for 15 min. 
The time spend in each chamber was analysed by Ethlog 2.2., as above, and the 
difference between post- and pre-conditioning time spent in each chamber was 
calculated to determine the preference score for each chamber. 
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4.2.4. Reward effects of morphine after chronic morphine administration 
 
 The evaluation of the reward effects of morphine after chronic morphine 
treatment was performed in a Plexiglas apparatus with the dimensions described 
above. The visual and tactile cues in the conditioning chambers, optimized above, were 
as follows: one chamber with a floor constituted by 0.5 cm diameter metal rods spaced 
2 cm and walls with alternating 3 cm wide black and white horizontal stripes; the 
second chamber with a mesh wire floor and walls with alternating wide black and white 
vertical stripes. The multi-trial conditioning protocol was chosen to perform the CPP 
test. 
 Rats were placed in the neutral chamber with full access to all chambers for 15 
min for 2 consecutive days, Day 1 was used for habituation purposes and on day 2 
(pre-conditioning phase; Scheme 6), rats behaviour was recorded for 15 minutes, as 
explained above. Rats spending less than 20% or more than 80% of the entire time in 
one of the chambers were excluded. Each rat was then randomly assigned to a 
treatment group and a conditioning chamber/environment in a counterbalanced 
fashion. Immediately after recording their behavior, the rats were implanted with 
osmotic mini-pumps filled with morphine (45 µg-1.µL-1.h-1) or saline for the chronic 
treatment (Scheme 6). On days 3-8 (conditioning phase; Scheme 6) one group of 
animals was subcutaneously injected with saline or morphine (10 mg/Kg) once a day 
on alternate days (saline mini-pumps group n = 7; morphine mini-pumps group n = 8). 
The animals were placed into the designated conditioning chamber for 1 hour. 
immediately after injection (Scheme 6 – item 2). The animals from the control group 
(saline mini-pumps group n = 4; morphine mini-pumps group n = 3) were 
subcutaneously injected with saline every day and placed into the designated 
conditioning chamber for 1 hour immediately after injection (Scheme 6 – item 1). On 
day 9 (post- conditioning phase; Scheme 6) rats were placed in the neutral chamber in 
a drug-free state, with access to all chambers, their behaviour was recorded for 15 min 
and the videos were analyzed by Ethlog 2.2 to determine the difference between post- 
and pre-conditioning time spent in each chamber. The number of chamber crossings 
was also analysed as it is considered a good indicator of locomotor activity [105, 106]. 
 The statistical analysis was performed by two-way ANOVA followed by Tukey 
post-hoc test for multiple comparisons. 
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Scheme 6: Evaluation of the reward effects of morphine after chronic morphine administration by the CPP test. Animals 
were allowed a 15 min period of habituation at Day 1 and were recorded on Day 2 (pre-conditioning phase) to ascertain 
preferences. Mini-pumps filled with morphine (45 µg-1.µL-1.h-1) or saline for chronic treatment were implanted on Day 2 
immediately after behavioural recording. Days 3-8 (conditioning phase): one group (1) received saline (S) s.c every day 
and the other group (2) received morphine (M, 10 mg/Kg) or saline on alternate days. Immediately after injection the 
animals were placed in the assigned chamber/environment for 1 hour each day. On day 9 (post-conditioning phase) 
animals were allowed to explore the apparatus in a drug free state for 15 min and were recorded to ascertain 
preferences. 
 
4.2.5. Effects of MOR knock-down at the DRt on morphine reward after chronic 
morphine administration 
 
 The evaluation of the effects of MOR knock-down at the DRt on morphine 
reward was performed in a Plexiglas apparatus with the dimensions and characteristics 
described above. 
 Rats were placed in the neutral chamber with full access to all chambers for 15 
min for 2 consecutive days, Day 1 was used for habituation purposes and on day 2 
(pre-conditioning phase; Scheme 6), rats behaviour was recorded for 15 minutes, as 
explained above. Rats spending less than 20% or more than 80% of the entire time in 
one of the chambers were excluded. Each rat was then randomly assigned to a 
treatment group and a conditioning chamber/environment in a counterbalanced 
fashion. Immediately after recording their behavior, the rats were stereotaxically 
injected MOR-R into the left DRt (n = 3), as decribed above, and implanted with 
osmotic mini-pumps filled with morphine (45 µg-1.µL-1.h-1) for the chronic treatment 
(Scheme 7). On days 3-8 (conditioning phase; Scheme 7) the animals were 
subcutaneously injected with saline or morphine (10 mg/Kg) once a day on alternate 
days. The animals were placed into the designated conditioning chamber for 1 hour 
immediately after injection (Scheme 7). On day 9 (post- conditioning phase; Scheme 7) 
rats were placed in the neutral chamber in a drug-free state, with access to all 
chambers, their behaviour was recorded for 15 min and the videos were analyzed by 
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Ethlog 2.2 to determine the difference between post- and pre-conditioning time spent in 
each chamber. The number of chamber crossings was also analysed. 
 The statistical analysis was performed by was one-way ANOVA followed by 
Tukey post-hoc test for multiple comparisons. 
 
 
Scheme 7: Effects of MOR knock down at the DRt on morphine reward. Animals were allowed a 15 min period of 
habituation at Day 1 and were recorded on Day 2 (pre-conditioning phase) to ascertain preferences. MOR-R was 
injected at the DRt and mini-pumps filled with morphine (45 µg-1.µL-1.h-1) for chronic treatment were implanted on Day 
2 immediately after behavioural recording. Days 3-8 (conditioning phase): the animals received morphine (M, 10 mg/Kg) 
or saline on alternate days. Immediately after injection the animals were placed in the assigned chamber/environment 
for 1 hour each day. On day 9 (post-conditioning phase) animals were allowed to explore the apparatus in a drug free 
state for 15 min and were recorded to ascertain preferences. 
 
 
 
5. Material processing for histological and 
immunohistochemical analysis 
 
 After the last behavioral evaluation, the animals that received lidocaine 
injections were deeply anaesthetized by an overdose of sodium pentobarbital (65 
mg/Kg i.p.), injected with 0.5 µl of 0.6% Chicago sky blue dye (Sigma, St. Louis, USA) 
through the guide cannula and sacrificed by decapitation. After decapitation, the brain 
was removed and immersed in a fixative solution containing 4% paraformaldehyde in 
0.1 M PB, pH 7.2 (Appendix A) for 4h followed by 30% sucrose in 0.1M PB, pH 7.2 
overnight at 4ºC. 
 At the completion of the experiments performed with naïve animals used to 
study the time course effects of chronic morphine administration and all animals 
injected with the lentiviral vectors, the animals were anaesthetized by an overdose of 
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sodium pentobarbital (65 mg/Kg i.p.). The animals were then placed in the supine 
position, the abdomen and the thorax were opened to expose the heart and 0,2 mL of 
heparine (Braun Medical,  Portugal) were injected into the left ventricle. A catheter was 
then introduced into the ascending aorta for perfusion with 200 mL of calcium-free 
Tyrode’s solution (Appendix  A), followed by 800 mL of fixative solution containing 4% 
paraformaldehyde in 0.1 M PB,  pH 7.2 (Appendix A). The brains were removed, 
immersed in fixative for 4 hours followed by 30% sucrose in 0.1M phosphate-buffered 
saline (PBS) overnight, at 4ºC.  
 The brainstems of all animals were serially cut in a freezing microtome at 40 
µm, collected in 4 sets and stored in a cryoprotector solution (Appendix A) at -20ºC. 
Brainstem sections from naïve animals were used for the immunohistochemical 
analysis of MOR and pCREB. Brainstem sections from all animals injected with the 
lentiviral vectors were used for the immunohistochemical analysis of MOR. 
 
6. Histological verification of injection sites 
 The location of the injection site of animals injected with lidocaine was 
determined by the location of the Chicago sky blue dye after counterstaining medullary 
sections encompassing the DRt with thionin. Only animals with cannula correctly 
targeting the DRt were included in data analysis. 
 To analyze the transduction patterns of the lentiviral vectors, one set of 
brainstem sections from animals injected with LV-Control were mounted on gelatine-
coated slides, cover slipped with a solution of glycerol diluted in PB (1vol/3vol) and 
analyzed in an ApoTome Slider (Zeiss®) fluorescence microscope with an excitation 
length of 488 nm. EFGP positive cells were plotted on diagrams of medulla oblongata 
sections. MOR-R vectors also carry the EFGP transgene (Figure 8) but its expression 
levels are undetectable, likely due to the RNA interference reaction induced by 
antisense RNA of MOR which degrades EGFP RNA placed in the second position of 
the bicistronic construct. Therefore the location of the injection sites of MOR-R-
injected-animals was determined by checking the position of the needle tract after  
counterstaining medullary sections encompassing the DRt with thionin (Appendix A) 
[107]. Only animals with vector injections centred in the DRt were included in data 
analysis. 
 
 
  
FCUP 
Unravelling the role of a pain facilitatory area of the brain during chronic opioid exposure 43 
 
 
7. Immunohistochemical analysis. 
7.1. pCREB immunodetection. 
 One in every fourth brainstem section, after washing with PBS, was incubated 
with a 30% Hydrogen peroxide solution to block endogenous peroxidase activity, 
followed by an incubation with a blocking solution (Glycine + 10% PBS-T) to prevent 
the nonspecific binding of the antibodies. After blocking, the sections were incubated 
with a rabbit polyclonal anti-pCREB antibody (Neuromics; U.S.A.)  in  PBS-T  at  
1:10000  for  48  hours  at  4°C.  After  washing  with  PBS-T  the  sections were 
incubated for 1h with a swine biotinylated anti-rabbit serum (Dako, Denmark)  diluted  
in  PBS-T  containing  2%  normal  swine  serum.  Sections were washed again and the 
detection of the immunoreaction was performed using the ABC solution (1:200; ABC; 
Vector Laboratories, U.S.A) as above. The sections were mounted on gelatin-coated 
slides, cleared in xylol and coverslipped with Eukitt. Five sections encompassing the 
rostro-caudal extent of the DRt were taken from each animal and photomicrographs of 
the DRt were taken using a Zeiss® light microscope with a high-resolution digital 
camera.  The number of pCREB positive nucleus/particles was calculated using an 
automated cell counting in the ImageJ® software. Briefly, all images were transformed 
into a 8-bit greyscale followed by an adjustment of the threshold, to highlight the 
structures to be counted. Then the images were converted to a binary watershed 
image to separate overlapped particles. The statistical analysis was performed using 
an unpaired t-test. 
 
7.2. MOR immunodetection 
 One in every fourth brainstem section, after washing with PBS, was incubated 
with a 30% Hydrogen peroxide solution to block endogenous peroxidase activity, 
followed by an incubation with a blocking solution (Glycine + 10% PBS-T) to prevent 
the nonspecific binding of the antibodies. After blocking, the sections were incubated 
with rabbit polyclonal anti-MOR antibody (Neuromics; U.S.A.)  in  PBS-T  at  1:1000  for  
48  hours  at  4°C.  After  washing  with  PBS-T  the  sections were incubated for 1h 
with a swine biotinylated anti-rabbit serum (Dako, Denmark)  diluted  in  PBS-T  
containing  2%  normal  swine  serum.  Sections were washed again and the detection 
of the immunoreaction was performed using the ABC solution (1:200; ABC; Vector 
Laboratories, U.S.A) as above. The sections were mounted on gelatin-coated slides, 
cleared in xylol and coverslipped with Eukitt. Five sections encompassing the rostro-
caudal extent of the DRt were taken from each animal and the numbers of MOR 
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neurons into the DRt were counted using an Olympos® light microscope with a high-
resolution digital camera. The statistical analysis was performed by was two-way 
ANOVA followed by Tukey post-hoc test for multiple comparisons. 
 
7.3. Double immunodectetion of MOR and pCREB 
 
 One in every fourth brainstem section, after washing with PBS, was incubated 
with a 1% sodium borohydride solution to reduce the tissue autofluorescence followed 
by an incubation with a blocking solution (Glycine + 10% PBS-T) to prevent the 
nonspecific binding of the antibodies. After blocking, the sections were incubated with a 
guinea-pig polyclonal anti-MOR antibody (Neuromics; U.S.A.)  in  PBS-T  at  1:500  for  
72  hours  at  4°C. After  washing  with  PBS-T  the  sections were incubated for 1h with 
a goat biotinylated anti-guinea-pig serum (Dako, Denmark)  diluted  in  PBS-T  
containing  2%  normal  goat  serum.  Sections were washed again with PBS-t and 
were incubated with streptavidin Alexa 488 (Molecular Probes®) at 1:500 for 1h. After 
that, sections were again incubated with a blocking solution as above, followed by the 
incubation with rabbit polyclonal anti-pCREB antibody (Neuromics; U.S.A.)  in  PBS-T  
at  1:1000  for  48  hours  at  4°C. After washing with PBS-T the sections were 
incubated for 1h with a donkey anti-rabbit Alexa 594 (Molecular Probes®). The 
sections were mounted on gelatin-coated slides, coverslipped with glycerol–phosphate 
buffer (3:1, vol/vol) and stored at 4°C. Five sections encompassing the rostro-caudal 
extent of the DRt were taken from each animal and the total number of MOR-IR 
neurons and double-IR for MOR and pCREB were counted using ApoTome Slider 
(Zeiss®) fluorescence microscope. The statistical analysis was performed using the 
unpaired t-test. 
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Results 
 
1. Effects of chronic morphine administration on pain behaviors 
  
1.1.  Effects on naïve animals 
 The effects of chronic morphine administration on naïve animals were tested 
before and at 2, 4 and 7 days after mini-pumps implantation (Scheme 1) by the von 
Frey and hot plate tests.  In the von-Frey  test,  animals  chronically  administered  with  
morphine  showed  a  significant decrease of withdrawal thresholds at day 4 (p=0.0128; 
Figure 16 A) and day 7 (p=0.0001; Figure 16 A) compared to baseline. At day 7, the 
withdrawal threshold of the morphine group was also significantly lower than in the 
saline group (p=0.0012; Figure 16 A). No significant differences were observed in the 
saline group compared to baseline. 
 In the hot plate test, animals treated with morphine showed a significant 
decrease of the withdrawal latency at day 4 (p= 0.0094; Figure 16 B) and day 7 
(p=0.0001; Figure 16 B) compared to baseline. At day 7, the withdrawal latency of the 
morphine group was also significantly lower than in the saline group (p=0.0129; Figure 
16 B). No significant differences were observed in the saline group compared to 
baseline.   
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Figure 16: Time course effects of morphine administration on mechanical allodynia tested by the von Frey test (A) and 
on thermal hyperalgesia tested by the hot plate test (B). Data are presented as mean ± SEM.  (saline – blue line n=6; 
morphine – red line  n=6 # p ˂ 0. 05; ## p ˂ 0. 01; ### p ˂ 0.001 vs. BL; * p ˂ 0. 05; ** p ˂ 0.01  saline vs treated group.) 
 
  
1.2.  Effects on neuropathic animals 
 
 The effects of the chronic morphine administration were tested before and at 2, 
4 and 7 days after mini-pumps implantation (Scheme 4) by the von Frey, pin prick and 
acetone tests.  In the von-Frey test, no significant differences were observed within 
each group and  between both groups (Figure 17 A).In the pin-prick test, the animals  
chronically administered with morphine showed a significant increase of the withdrawal 
duration at day 4 (p=0.0027; Figure 17 B) and day 7  (p=0.0001; Figure 17 B) 
compared to baseline. At day 7, the withdrawal duration in the morphine group was 
also significantly higher than in the saline group (p=0.0159; Figure 17 B). No significant 
differences were observed in the saline group compared baseline.   
A 
B 
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 In the acetone test, animals treated with morphine showed a significant 
increase of the withdrawal duration at day 7 compared both to BL (p=0.0287;  Figure  
17 C) and the saline group (p=0.0289; Figure 17 C). No significant differences were 
observed in the saline group compared to baseline.    
 
Figure 17: Time course effects of morphine administration on mechanical allodynia tested by the von Frey test (A), 
mechanical hyperalgesia tested by the pin prick test (B) and cold allodynia tested by the acetone test (C). Data are 
presented as mean ± SEM.  (saline – blue line n=6; morphine – red line (n=6) # p ˂ 0. 05; ## p ˂ 0. 01; ### p ˂ 0.001 vs. 
BL; * p ˂ 0. 05 saline vs treated group). 
   
 
2. Effects of chronic morphine administration on the reward behavior 
 
2.1. Optimization of the conditioned place preference test 
 
2.1.1 Visual cues 
 
 Two different visual contexts were tested in the CPP apparatus. One 
conditioning chamber had walls with alternating 3 cm wide black and white horizontal 
stripes. The second conditioning chamber had alternating 3 cm wide black and white 
vertical stripes. The chambers were separated by a neutral chamber with black 
Plexiglas walls. 
A B 
C 
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 The animals did not show a preference for any context (Figure 18). Given the 
unbiased results obtained, these two visual contexts were elected to carry on the CPP 
test. 
 
Figure 18: Optimization of the visual cues of the CPP test. The CPP apparatus contained one chamber with walls 
containing alternating 3 cm wide black and white horizontal stripes and a second chamber containing alternating 3 cm 
wide black and white vertical stripes. The chambers were separated by a neutral chamber with black Plexiglas walls. 
Data are presented as mean ± SEM (n=5). 
 
2.1.2. Tactile cues 
 
 To optimize the tactile cues, four different combinations of floors in the 
conditioning chambers were tested: i) “Mesh wire floor vs black Plexiglas floor”; ii) 
“Mesh wire floor vs Corn cob floor”; iii) “Mesh wire floor vs metallic floor with circles” 
and iv) “Mesh wire floor vs metal bars floor”. 
 The animals presented a clear preference for the compartment presenting the 
mesh wire floor when it was combined with the black Plexiglas (Fig. 19 A), corn cob 
(Fig. 19 B) and metallic floor with circles (Fig. 19 C). When the mesh wire floor was 
combined with the metal bars floor, the animals no longer presented any preference 
(Figure 19 D). Given the unbiased results obtained with the “Mesh wire floor” and the 
“Metal bars floor” combination, these two tactile contexts were elected to carry on the 
CPP test. 
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Figure 19: Optimization of the tactile cues of the CPP test. Four different environments were tested: Mesh wire floor vs 
black Plexiglas floor (A; n=1); Mesh wire floor vs Corn cob floor (B; n=1); Mesh wire floor vs metallic floor with circles (C; 
n=4) and Mesh wire floor vs metal bars floor (D; n=9). Data are presented as mean ± SEM. 
 
 
2.1.3. The number of conditioning trials 
 
 To optimize the number of conditioning trials, the animals first underwent the 
pre-conditioning phase during which they were placed in the neutral chamber with full 
access to all chambers and their behaviour was recorded for 15 minutes. The pre-
conditioning phase was followed by a conditioning phase during which the animals 
were administered saline or morphine (10 mg/Kg; s.c.) in a specific compartment. We 
tested a single-trial conditioning phase protocol during which the animals, were 
subcutaneously injected with saline and randomly placed in a conditioning chamber for 
1 hour. Four hours later, the animals were subcutaneously injected with morphine (10 
mg/Kg) and placed in the other chamber for 1 hour. Then we tested a multi-trial 
conditioning phase protocol during which the animals were subcutaneously injected 
A B 
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with saline or morphine (10 mg/Kg) once a day on alternate days for 6 days. The 
animals were placed into the designated conditioning chamber for 1 hour immediately 
after the injection. The conditioning phase was then followed by the post-conditioning 
phase during which the rats were placed in the neutral chamber in a drug-free state, 
with access to all chambers, their behaviour was recorded for 15 min and the 
difference between pre- and post-conditioning time spent in the morphine-paired 
chamber was determined. 
 The animals that underwent the multi-trial conditioning protocol, showed higher 
preference scores in the morphine-paired chamber compared to the animals that 
underwent the single-trial conditioning protocol (Figure 20). Given the higher scores of 
the multi-trial conditioning protocol, this conditioning protocol was elected to carry on 
the CPP test. 
 
 
 
Figure 20: Optimization of the number of the conditioning trials. During the conditioning phase, the animals were 
administered saline or morphine (10 mg/kg; s.c.) and then placed on a specific compartment. In the single-trial protocol 
(n = 3) the animals, were subcutaneously injected with saline and randomly placed on a conditioning chamber, 4 hours 
later, they were subcutaneously injected with morphine (10 mg/Kg) and placed in the other chamber. In the multi-trial 
conditioning protocol (n = 3) the animals were subcutaneously injected with saline or morphine (10 mg/Kg) once a day 
on alternate days for 6 days. On the post-conditioning day, rats behavior was recorded for 15 min and the videos were 
analyzed to determine the difference between pre - and post -conditioning time spent in the morphine-paired chamber. 
Data are presented as mean ± SEM. 
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2.2. Effects of chronic morphine administration on morphine reward 
 
 
 The CPP test was performed on animals chronically administered morphine (45 
µg-1.µL-1.h-1; n=11) or saline (n=11). Animals chronically treated with saline and 
conditioned with morphine (10 mg/kg; s.c.) on alternate days (n=7) spent longer time in 
the morphine-paired chamber compared to control animals conditioned with saline 
(n=4) every day (p= 0.0087;Figure 21). Animals chronically treated with morphine and 
conditioned with morphine in alternate days (n=8) spent significantly less time in the 
morphine paired chamber compared to animals chronically treated with saline and 
conditioned with morphine in alternate days (p=0.0438; Figure 21).  
 We also analyzed the effect of chronic morphine treatment in the locomotion by 
analyzing the number of compartment crossings (Table 4). The statistical analysis 
reveals that in general chronic morphine treatment induces a higher number of 
crossings compared to chronic saline treatment (F1,19=5.26; p = 0.03). Within the 
chronic morphine treated group the number of compartment crossing was statistically 
higher when conditioning was performed with saline (p = 0.0002). Nonetheless, when 
conditioning was performed with morphine, the number of crossings was not 
statistically different between animals chronically treated with saline and morphine (p = 
0.98). Within the chronic saline treated group no differences were observed between 
conditioning with saline and morphine (p = 0.25). 
 
 
Table 4: Effects of chronic morphine administration on locomotor activity. Locomotion was evaluated by the number of 
compartment crossings. Data  are presented as mean ± SEM. *** p ˂ 0. 001 vs. CPP-Saline/Saline of the morphine 
treated group. 
Saline mini-pumps Morphine mini-pumps 
Saline/Saline Morphine/Saline Saline/Saline Morphine/Saline 
73.25± 14.1 
 
53.5± 5.72 
 
 
111±12.2 
 
 
50.875± 2.01
***
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Figure 21:  Effects of chronic morphine administration on morphine reward. During conditioning morphine (orange bars - 
10 mg/kg, s.c.) was injected in alternate days in animals chronically administered with saline (n=7) or morphine (n=8). 
Control animals were injected saline (white bars) every day in animals chronically administered with morphine (n=3) or 
saline (n=4). Data are presented as mean ± SEM. ( *p ˂ 0. 01 vs. CPP-Saline/Saline; # p ˂ 0. 05 vs. CPP-
Morphine/Saline of the morphine treated group). 
 
 
3. Involvement of the DRt in chronic morphine effects 
 
3.1. Effects of DRt inactivation on nociceptive behavior 
 
 DRt inactivation was achieved by local injection of lidocaine. The effects of 
lidocaine on nociceptive behavior were 7 days after mini-pump implantation before 
(Figure 22; -Lido) and 30 min after (Figure 22; +Lido) lidocaine injection (Scheme 2).  
 In the von-Frey test, before lidocaine injection (i.e. at day 7 after mini-pump 
implantation) animals chronically administered with morphine showed a significant 
decrease of the withdrawal threshold compared with animals chronically administered  
with saline (p=0.0001;Figure 22 A). Lidocaine injection completely reversed the effects 
of chronic morphine (p=0.0001; Figure 22 A). No significant differences were observed 
after lidocaine injection on animals chronically administered with saline (Figure 22 A). 
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Figure 22: Effects of the DRt inactivation on mechanical allodynia tested by the von Frey test (A) and on thermal 
hyperalgesia tested by the hot plate test (B). Data are presented as mean ± SEM. ( Saline group n=6; morphine group 
n=6 ; ### p ˂ 0.001 vs. + Lido ** p ˂ 0. 01; *** p ˂ 0. 001vs. - Lido of the saline treated group). 
 
 In  Hot plate  test, before lidocaine injection animals chronically administered 
with morphine showed a significant decrease of the withdrawal latency compared with 
animals chronically administered with saline (p=0.0044;Figure 22 B). Lidocaine 
injection completely reversed the effects of chronic morphine (p= 0.0001; Figure 22 B). 
No significant differences were observed after lidocaine injection on animals chronically 
administered with saline. 
 Lidocaine injection in neighboring areas of the DRt like the VLM and Sol did not 
revert the effects of chronic morphine both in the von Frey (Fig. 23 A and C) and hot 
plate test (Fig. 23 B and D).  
 
 
 
A B 
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Figure 23: Effects of the VLM and Sol inactivation on mechanical allodynia tested by the von Frey test (A and C) and on 
thermal hyperalgesia tested by the hot plate test (B and D). Data are presented as mean ± SEM (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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3.2. Effects of chronic morphine on pCREB and MOR expression at the DRt 
 
 
 Chronic morphine administration in naïve animals induced a significant increase 
of pCREB at the DRt compared with animals chronically treated with saline (p= 0.0304; 
Figure 24). 
 
 
 
Figure 24: Effects  of  chronic  administration  of  morphine  on  the  expression  of  pCREB  at  the  DRt.  
Representative  photomicrographs of pCREB labeling at the DRt of animals chronically administered with  morphine (A) 
and saline (B). Scale bar in A: 100m (B is at the same magnification). Data in C are presented as mean ± SEM 
(n=6/group *p<0,05).  
 
 
 Chronic morphine administration in naïve animals induced a significant increase 
in the number of MOR cells at the DRt compared with animals chronically treated with 
saline (p= 0.0022; Figure 25 A). The percentage of double labelled cells for MOR and 
pCREB (Figure 25 C) was high both in saline and morphine treated animals and did not 
differ berween the groups (p= 0.2098 ; Figure 25 B); Saline treated animals showed an 
average of 92.6 ± 1.73% of co-localization (201.0 ± 11.0 double labelled cells; Figure 
25 A and B). Morphine treated animals showed an average of 95.4 ± 0,85% co-
localization (Figure 25 B). 
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Figure 25: Effects  of  chronic  administration  of  morphine  on  the  expression  of  MOR and pCREB . Total number of 
neurons single labelled for MOR and double labelled for MOR and pCREB (A); Percentage of neurons that co-localize 
with CREB (B) in animals chronically treated with saline and morphine.  Representative photomicrograph  of double-
labeled neurons for MOR and pCREB (yellowish; double arrows) and pCREB labeling (sigle arrow) at the DRt (C). Data 
in A and B presented as mean ± SEM (saline n=6; morphine n=5) 
 
 
3.3. Effects of MOR Knock-down at the DRt 
 
3.3.1. Pattern of lentiviral transduction   
 
 The pattern of lentiviral transduction was analyzed in animals injected with LV-
Control and with the injection site centered at the DRt (Figure 26 A, B). In those 
animals, the injection site was constituted by a central dark zone corresponding to the 
needle tract with numerous EGFP+ neurons (Figure 26 B) around this central region. All 
EGFP + neurons were located within the boundaries of the DRt which indicates  that  
injections  correctly  placed  at  the  DRt  show  a  pattern  of  lentiviral  transduction  
restricted to the DRt.   
 The injection site of MOR-R-injected animals was analyzed in medullary 
sections stained with thionin, because EGFP expression from these constructs (Figure 
8) was almost undetectable. The injection site was identified by the presence of the 
needle tract in the DRt. In those animals the injection site was constituted by a central 
dark core corresponding to the needle tract surrounded by a peripheral zone lightly 
stained by thionin (Figure 26 C). Only animals with the injection site placed at the DRt 
were included in data analysis. 
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Figure 26: Localization of the injection site in the DRt. (A) Diagram depicting the location of the DRt, at 5.60 mm caudal 
to the interaural line adapted from the Paxinos and Watson (2007 Paxinos) (B) Fluorescence photomicrograph of the 
injection site at the DRt showing EGFP neurons better depicted in the insert. (C) Representative photomicrograph of a 
thionin-stained section illustrating a correct vector injection at the DRt. Scale bar in B: β00 μm (C is at the same 
magnification). 
 
3.3.2. Effects of lentiviral transduction on MOR expression 
 
 MOR expression at the DRt was evaluated in naïve and SNI animals chronically 
treated with saline or morphine and injected with LV-cont or MOR-R. LV-cont-injected 
animals treated with morphine showed increased numbers of MOR-IR cells compared 
to LV-cont-injected animals treated with saline both in naïve (p=0.0001; Figure 27 C) 
and SNI animals (p=0.0001; Figure 27 C). In naïve rats, MOR-IR-injected animals 
showed a significant reduction of MOR-IR cells compared LV-cont-injected rats both 
after chronic treatment with saline (p=0.0001; Figure 27 C) and morphine (p=0.0001; 
Figure 27 C). In SNI animals MOR-IR also induced a significant reduction of MOR-IR 
cells compared to LV-cont-injected rats both after chronic treatment with saline 
(p=0.0040 Figure 27 C) and morphine (p=0.0001; Figure 27 C). 
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Figure 27: Evaluation of MOR expression by immunohistochemistry after injection of a lentiviral vector that knocks down 
MOR (MOR-R vector) and a control vector (LV-cont) at the DRt. Representative photomicrographs of MOR-IR cells in 
the DRt of naïve rats chronically treated with morphine and injected with LV-cont (A)  and MOR-R (B). Typical MOR 
immunolabeling  is marked by arrows. Scale bar in B: 50m (A is at the same magnification). Data in C are represented 
as mean ±SEM (naïve animals treated with saline LV-Cont n = 7; MOR-R n = 6; or  morphine: LV-Cont n= 6; MOR-R 
n=6 and SNI animals treated with saline: LV-Cont n = 6; MOR-R n = 5; or morphine: LV-Cont n= 5; MOR-R n=6; ###p ˂ 
0. 001 vs. LV-Cont  of saline group; *p ˂ 0. 05; *** p ˂ 0. 001 vs. Lv-Cont). 
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3.3.3. Effects of lentiviral transduction on nociceptive behavior 
3.3.3.1. Effects on naïve animals 
 
 The  effect  of  the  MOR  knock-down  at  the  DRt on naïve animals during  
chronic  treatment  with  morphine  was  evaluated  before  and at 7 days after  the  
mini-pumps  implantation and stereotaxic injections of the lentiviral vectors (Scheme 3). 
 In von-Frey test, animals chronically treated with morphine and injected with the 
control vector showed a significant decrease of the withdrawal threshold compared to 
baseline (p=0.0001; Figure 28 A). Animals injected with MOR-R and chronically 
exposed to morphine also showed a significant decrease of the withdrawal threshold 
compared to baseline (p=0.0001; Figure 28 A). Nonetheless, this decrease was less 
important than that observed in animals injected with the control vector, indeed the 
withdrawal thresholds of MOR-R-animals were significantly higher than in the LV-
Control group (p= 0.0149; Figure 28 A). In animals chronically treated with saline, the 
injection of LV-Control did not induce significant alterations compared to baseline. 
MOR-R caused a significant decrease of the withdrawal threshold compared to the 
baseline (p= 0.0001; Figure 28  A) and the LV-Control group (p= 0.0105; Figure 28 A). 
  In the Hot plate test, animals chronically treated with morphine and injected with 
LV-Control showed a significant decrease in the withdrawal latency compared to 
baseline (p= 0.0001; Figure 28 B). Animals injected with MOR-R showed higher 
withdrawals latencies compared to the LV-Control group (p= 0.0032; Figure 28 B) with 
values similar to the baseline (Figure 28 B). In animals chronically treated with saline, 
the injection of LV-Control did not induce significant alterations compared to baseline 
(Figure 28 B). MOR-R induced a significant decrease of the withdraw latency 
compared to baseline (p = 0.0129; Figure 28 B).  
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Figure 28:  Effects  of  MOR  knock-down at the DRt on mechanical allodynia tested by the von Frey test (A) and on 
thermal hyperalgesia tested by the hot plate test (B) during  chronic  saline or morphine  administration. Data are 
presented as mean ± SEM. (chronic morphine treatment: LV-Control-injected n=6, MOR-R-injected n=5; chronic saline 
treatment: LV-Control-injected n=5; MOR-R-injected n=6;  * p ˂ 0. 05; **p˂ 0. 01; *** p ˂ 0. 001). 
 
3.3.3.2. Effects on SNI animals 
 
 The  effect of MOR knock-down at the DRt on SNI animals during  chronic  
treatment  with  morphine  was  evaluated  before  and  7  days  after  the  mini-pumps  
implantation and stereotaxic injections (i.e 3 to 4 weeks after SNI induction; Sheme 5). 
 In von-Frey test no significant differences were observed (Figure 29 A). 
 In the pin-prick test, animals chronically treated with morphine and injected with  
the control vector showed a significant augmented withdrawal duration compared to 
baseline (p=0.0045; Figure 29 B). Animals injected with MOR-R showed a significantly 
lower withdrawal duration compared to the LV-Control group (p= 0.0014: Figure 29 B) 
with values similar to the baseline (Figure 29 B). In animals chronically treated with 
saline, the injection of LV-Control did not induce significant alterations compared to 
baseline (Figure 29 B). MOR-R induced a significant increase of the withdrawal 
duration compared both to the LV-Control group (p= 0.0017; Figure 29 B) and baseline 
(p= 0.0001; Figure 29 B). 
 In the acetone test, animals chronically treated with morphine and injected with 
LV-Control showed a significant increase of the withdrawal duration compared to 
baseline (p= 0.0041; Figure 29 C). Animals injected with MOR-R showed a significantly 
lower withdrawal duration compared to the LV-Control group (p= 0.0001; Figure 29 C) 
with values similar to the baseline (Figure 29 C). In animals chronically administered 
with saline the injection of LV-Control did not induce significant alterations compared to 
baseline (Figure 29 C). MOR-R induced a significant increase of the withdraw duration 
A B 
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compared both to the LV-Control group (p= 0.0001; Figure 28 C) and baseline (p= 
0.0001; Figure 29 C). 
 
 
Figure  29:  Effects of MOR knock-down at  the DRt on mechanical allodynia tested by the von Frey test (A), mechanical 
hyperalgesia tested by the pin prick test (B) and cold allodynia tested by the acetone test (C) during chronic saline or 
morphine administration. Data are presented as mean ± SEM. (chronic morphine treatment: LV-Control-injected n=6, 
MOR-R-injected n=6; chronic saline treatment: LV-Control-injected n=5; MOR-R-injected n=6  ** p ˂ 0. 01; *** p ˂ 0. 
001) 
 
A 
B 
C 
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3.3.4. Effects of lentiviral transduction on reward behavior 
 
 The CPP test was performed on animals chronically administered morphine (45 
µg-1.µL-1.h-1) and injected with MOR-R at the DRt. Animals injected with MOR-R and 
chronically treated with morphine and conditioned with morphine (10 mg/Kg; s.c.) (n=3) 
spent more time in the morphine-paired chamber compared to animals only chronically 
treated with morphine and conditioned with morphine  (n=8) although this comparison  
did not reach statistical significance (Figure 30). 
 The statistical analysis showed no differences in the number of crossings 
between the groups (Table 5). 
 
 
Figure  30:  Effects of MOR knock-down at the DRt on morphine reward. During conditioning morphine (10 mg/kg, s.c. - 
orange bars) was injected in alternate days in animals chronically administered with saline (n=7) or morphine (n=8). In 
MOR-R-injected animals morphine (red bar) was injected in alternate days in animals chronically administered with 
morphine (n=3). Data are presented as mean ± SEM. 
Table 5:  Effects of  chronic  morphine administration  on  locomotor activity.  Locomotion was shown as the number of 
compartment crossings. Data are means ± SEM. 
Saline mini-pumps Morphine mini-pumps 
Morphine/Saline Morphine/Saline Morphine/Saline+ MOR-R 
 
53.5± 5.72 
 
 
50.875± 2.01 
 
 
63.75± 3.42 
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Discussion and Conclusions 
 
 The results gathered in the present thesis show that chronic administration of 
morphine induces mechanical and thermal sensibility in naïve animals and, an 
aggravation of pre-existing pain in animals with chronic neuropathic pain. In the CPP 
test, neuropathic animals chronically treated with morphine failed to show preference 
for the morphine-paired chamber which indicates a loss of the reward effect of 
morphine. Inactivation of the DRt with lidocaine fully reversed mechanical allodynia and 
thermal hyperalgesia of morphine-infused animals. Chronic morphine treatment 
induces an increase of pCREB and MOR expression at the DRt. Lentiviral-mediated 
MOR knock-down at the DRt prevented the development of opioid-induced 
hyperalgesia and in the CPP test, the preliminary results obtained indicate a small 
reversion of the loss of the reward effect of morphine. 
  
1. Effects of chronic administration of morphine 
 Our results show that chronic morphine administration in naïve animals induce 
enhanced pain responses during acute pain induction, which is in agreement with 
previous reports [108-110]. Moreover, we show for the first time that chronic morphine 
administration induces an aggravation of pain in a chronic neuropathic pain model. 
These results are clinically relevant since opioid drugs are used in patients struggling 
with moderate and severe chronic pain [17, 34, 50]. 
 Unlike naïve animals, neuropathic animals did not show an aggravation of 
mechanical thresholds upon chronic morphine administration. This is probably due to 
technical issues. Indeed, due to neuropathic pain, animals respond to  the  lowest  
microfilament  available  (0.008 g),  therefore  it  was impossible  to  observe  further  
decreases  of  the  mechanical  threshold.  However, since in naïve animals chronic 
morphine induced a decrease of mechanical thresholds it is likely that in SNI animals 
this pain modality might be affected. 
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2.  Involvement of the DRt in OIH 
 
 The injection of lidocaine directly into the DRt fully reversed mechanical 
allodynia and thermal hyperalgesia after chronic morphine exposure. These results 
show that descending facilitation from the DRt is involved in OIH.  Furthermore, our 
results indicate that MOR is likely involved in increased DRt facilitation during chronic 
administration of morphine. Usually MOR exerts a inhibitory action by inhibiting AC 
activity, causing activation of Kir3 K+ channels and inhibition of the voltage-dependent 
Ca2+ channels, leading to hyperpolarization of the cell [111, 112]. This inhibitory effect 
would decrease DRt facilitation and MOR knock-down at the DRt would then lead to 
disinhibition of the DRt and thus hyperalgesia. The hyperalgesic effects observed in 
naïve animals or the aggravation of pain behaviors in SNI animals upon saline 
treatment are consistent with the inhibitory effects of MOR. Previous reports also 
confirm the inhibitory effects of opioids at the DRt in acute pain models [40, 44]. The 
opposite effects of MOR knock-down during chronic morphine, i.e. MOR knock-down 
prevented the development of OIH both in naïve and SNI animals, are more consistent 
with MOR mediating facilitatory effects. This switch of MOR signalling have been also 
reported during chronic morphine in vitro [111, 113-115], and at the locus coeruleus 
[112, 116] and at the nucleus acumbens [112]. 
 Accelerated desensitization, increased constitutive activity or endocytosis of the 
receptor are suggested as cellular adaptations to chronic morphine exposure [117]. 
The most likely explanation might lie on a switch on the G-protein coupled to MOR, 
from Gi/o to a Gs-protein, leading to an increase in AC, which causes augmented levels 
of cAMP, altering the hyperpolarized state of the neuron by changing the intracellular 
concentrations of Ca2+ and K+ [118, 119]. Futher corroborating this, chronic morphine 
exposure in naïve animals also increased pCREB levels at the DRt and MOR-IR cells 
colocalized with pCREB. The increased expression of pCREB during chronic morphine 
administration has been previously described in other areas like the nucleus of the 
solitary tract [59] and locus coeruleus [62]. The evaluation of the co-localization of 
MOR and pCREB in neurophatic animals was not performed but will be held in the 
future. 
 It is worth noting that chronic morphine increased MOR expression more 
significantly in naïve animals than in neuropathic animals. This may be the due to the 
neuropathy. Indeed, several studies reveal that chronic pain induces down-regulation 
of MOR signaling and expression [120, 121]. This decrease of the MOR expression 
likely contributes to increased descending facilitation during chronic pain [11, 122]. In 
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spite of this chronic treatment with morphine induces an increase of MOR expression, 
leading to an increase of pain sensibility characteristic of the OIH. 
 
3. Reward effects of morphine 
 Pain and reward are opponent and interacting processes with a large overlap of 
the brain systems that control them. Opioids are particularly important for processing 
the aspects of reward as well as the  processes of pain modulation [73]. Relief from an 
unpleasant state is usually associated with rewarding qualities. Pain relief is an 
important type of reward, in particular in chronic pain [73, 74], and has been proven in 
humans [123] and rats [124]. In fact, in the past years, the CPP test, has also been 
used for the assessment of ongoing pain both in inflammatory [125, 126] and in 
neuropathic pain models [127, 128]. 
 Our results show that chronic morphine exposure reversed the preference of 
the animals for the morphine-paired chamber. This loss morphine reward in 
neuropathic animals is not associated with sedative effects of morphine since the 
number of the compartments crossing is similar to the animals chronically treated with 
saline. On the contrary, the chronic administration of morphine in animals increased 
locomotor activity [105, 129] which was also demonstrated in our work in animals 
chronically administrated with morphine and conditioned with saline. 
 In the reward system, morphine binds to MOR expressed on GABAergic 
neurons which normally inhibit dopaminergic neurons in the VTA. MOR activation on 
GABAergic neurons leads to disinhibition of dopaminergic neurons witch induces an 
increase of dopamine release in the NAc [120]. Therefore, the loss of morphine reward 
should be the result of decreased inhibition of GABAergic neurons, also consistent with 
the switch of MOR activity, resulting thus in a reduction of dopamine release in areas 
involved in the reward system. 
 Given the overlap of these two systems, to assess the influence of pain 
modulatory areas in the reward system, we studied the effect of the MOR knock-down 
at the DRt on the effect of morphine reward. Our hypothesis is that during chronic pain, 
increased descending facilitation [11, 122] along with the aggravation of DRt 
descending facilitation, due to chronic morphine exposure shown by our results, likely 
lead to a less pain relief/reward (Figure 31). Therefore, if we reduce MOR expression 
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at the DRt, this should lead to more pain relief and consequently more morphine 
reward. 
 
 
 
 
 
 
 
 
 
Figure 31: Schematic representation of the relationship between descending facilitation and pain relief/reward. 
 
 Although these experiments were performed with a small number of animals, 
they are indicative of a reversion of the loss of the reward effect of morphine. 
Increasing the number of animals should reinforce these results. Our results suggest 
that the DRt is connected to the reward system. These connections are probably 
relayed by other areas connected to the DRt [130] that are involved both in pain and 
reward such as the amygdala, the dorsal and ventral striatum and insular cortex. In 
future studies it would be interesting to evaluate the effect of these connections on the 
effects of pain relief and reward mediated by morphine. 
 
4. Conclusions and future perspectives 
 
 Opioids are a common therapy to treat moderate and severe pain. Unravelling 
the molecular mechanisms involved in OIH is fundamental since, instead of relieving 
pain, these drugs may be responsible for hyperalgesia, in some patients.  
 We show in this thesis that prolonged exposure to opioids likely induces plastic 
changes in opioidergic circuits causing an exacerbation of DRt descending facilitation 
that contributes to OIH. In continuity of this thesis it would be interesting to further 
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extend the study of pCREB and MOR in neuropathic animals mainly by inhibiting some 
kinases responsible for the activation of CREB at the DRt. 
 Unveiling the molecular mechanisms behind OIH is the key to overcome its side 
effects, namely the loss of the pain relief observed after morphine chronic 
administration at the CPP test. In the future, it would be interesting to continue the 
studies of this thesis by evaluating the connections between the DRt and areas 
involved in pain and reward on the effects of pain relief mediated by morphine. 
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Appendix A: Composition of solutions  
 
1.  PHOSPHATE BUFFER SALINE (PBS) (1L)  
Phosphate buffer (PB) 0,1M pH=7,2:  
Na2 H2PO4H2O – 15,60g  
K2HPO4  – 17,4g  
H2O up to 1L  
PBS:  
PB 250 ml  
H2O up to 1L  
NaCl - 9g  
 
2. PHOSPHATE BUFFER SALINE WITH TRITON X-100 (PBS-T)  
PBS - 996ml  
Triton X-100 - 4ml 
  
3. TYRODE’S SOLUTION (1L)  
NaCl – 6,8 g  
KCl – 0,40g  
MgCl 2  6 H2O – 0,32 g  
MgSO 4 7 H2O – 0,1 g  
NaH 2 PO4 H2O – 0,17 g  
Glucose 1 g  
NaHCO 3  – 2,2 g  
H2O up to 1L  
 
4. CRYOPROTECTOR SOLUTION (1L)  
PB 0,1M pH=7,2 - 125 ml  
b FCUP Unravelling the role of a pain facilitatory area of the brain during chronic opioid exposure 
 
H2O - 375 ml  
Sucrose - 300g  
Ethylene glycol - 300ml  
PB 0,1M pH=7,2 up to 1L  
  
 5. THIONIN STAINING  
1. Solutions : 
Acid acetone: acetone / acetic acid (4 vol / 1 vol)  
0,1% thionin in 10% formalin  
 
2. Protocol : 
Incubate the slides in acid acetone for 5 min;   
Rinse with distilled water;   
Stain in formol-thionin for 1 minute;  
Rinse with distilled water;  
Dry at 37 ° C;   
Dehydrate in xylene for 5 min;   
Mount with Eukitt.  
  
